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1ABSTRACT
Th is study was undertaken to assess the feasibility of non-invasive sampling and assay of 
urinary gonadotropins for clinical evaluation of pubertal development. In the fi rst study, 
the concentrations of LH and FSH in concurrent serum and fi rst-morning-voided (FMV) 
urine samples of 820 children (486 boys and 334 girls, age 0-17 years) were determined 
with time-resolved immunofl uorometric assay (IFMA). Th e detection limit of IFMA 
was 0.018 IU/L for FSH, 0.015 IU/L for LH and 0.012 IU/L for LHspec. It was possible 
to measure the low prepubertal LH and FSH concentrations reliably in these samples due 
to the high sensitivity and low detection limits of IFMA. Th e correlation between serum 
and urinary gonadotropin values was high (r=0.751; p<0.001 for FSH and r=0.720; p<0.001 
for LH), and the urinary and serum concentrations were close to each other. Correcting 
urinary gonadotropin concentrations on the basis of urinary density or creatinine did not 
improve the correlation. Age-related changes in urinary LH and FSH (U-LH and U-FSH) 
were examined. Th e concentrations of U-LH and U-FSH decreased from birth until 
the child was a few months old, aft er which the upper range of the U-LH levels of girls 
remained stable at below 0.5 IU/L until age 9 years and of boys below 1.0 IU/L until age 
11 years. Th e upper range of the U-FSH levels of girls remained below 3.0 IU/L until age 
10 years and of boys below the same concentration until age 12 years. Th e median U-LH 
concentration during the prepubertal period was about 0.06 for girls and 0.07 for boys. 
For the boys, this fi gure rose 10-fold by age 11, 40-fold by age 12 and 50-fold by age 13-14. 
Th e overall increase in the median U-LH concentrations was 75-fold from 5 to 15 years 
and 35-fold from Tanner stage G1 to G5. Th e corresponding fi gures for girls were 30-fold 
by age 11, 70-fold by age 12 and 90-fold by age 14; the overall increase in median U-LH 
concentrations was 90-fold from 5 to 15 years and 40-fold from Tanner stage B1 to B5 
times. Th ese fi nding indicate that the U-LH concentrations of FMV samples obtained from 
clinically prepubertal children refl ect pubertal levels. Th e age-related changes in U-FSH 
concentrations were similar for boys and girls; the only diff erence was that the levels were 
generally higher for girls, in particular between ages 2–8 years. U-FSH reached a 5-fold 
level compared to prepubertal levels by the end of the puberty in both sexes. FMV U-LH, 
U-FSH and their ratios correlated well with the corresponding basal and GnRH-stimulated 
serum concentrations (P<0.001). Receiver operating characteristic (ROC) curve analyses 
of urinary and serum LH and FSH concentrations showed that FMV U-LH and U-LH/
U-FSH performed equally well as the GnRH test for diff erentiating early puberty (Tanner 
2) from prepuberty (Tanner 1) [area under the curve (AUC) 0.768-0.890 vs. 0.712-0.858]. 
FMV U-LH and U-LH/U-FSH performed equally well as basal S-LH for predicting a 
pubertal GnRH test result (AUCs 0.90–0.93). Among the tests studied, only FMV U-LH 
diff erentiated the transitions from Tanner stage 1 to 2 and Tanner stage 2 to 3 (p<0.001 for 
boys and p=0.003 for girls). Again, this corroborates that FMV U-LH is the most reliable 
tool for evaluation of pubertal development. Th erefore, FMV urinary LH determinations, 
which are non-invasive and, at most, minimally stressful for the child patient, can be used 
for preliminary diagnostic evaluation of pubertal development. It reduces the need for 
S-LH determinations and the GnRH stimulation tests, both invasive procedures.
Abstract
2TIIVISTELMÄ
Tämän tutkimuksen tarkoituksena oli arvioida virtsan gonadotropiinimäärityksen 
(kajoamaton tutkimus) käyttökelpoisuutta puberteettikehityksen kliinisessä arvioinnissa. 
Ensin tutkimme puberteetin eri vaiheissa olevilta 820 lapselta (486 poikaa ja 334 tyttöä, 
ikä 0–17 vuotta) otettujen seerumi- ja aamuvirtsanäytteiden LH- ja FSH-pitoisuudet 
käyttäen aikaerotteista immunofl uorometristä määritystä (IFMA). Erittäin herkän 
määritysmenetelmän toteamisrajat olivat seuraavat: FSH 0,018 IU/L, LH 0,015 IU/L 
ja LHspec 0,012 IU/L. Menetelmän herkkyyden ja matalien toteamisrajojen ansiosta 
sillä oli mahdollista mitata luotettavasti esipuberteettivaiheen matalahkoja LH- ja FSH-
pitoisuuksia virtsa- ja seeruminäytteistä. Seerumin ja virtsan gonadotropiiniarvot 
korreloivat voimakkaasti (FSH: r = 0,751, p < 0,001; LH: r = 0,720, p < 0,001), ja pitoisuudet 
virtsassa ja seerumissa olivat lähellä toisiaan. Virtsan gonadotropiinipitoisuuksien korjaus 
virtsan tiheyden tai kreatiniiniarvon perusteella ei parantanut korrelaatiota. Tutkittaessa 
virtsan LH- ja FSH-pitoisuuden (U-LH ja U-FSH) muutoksia iän myötä todettiin, että 
U-LH-arvot laskevat ensin muutaman kuukauden ikään asti ja sen jälkeen ylimmät arvot 
ovat tytöillä 9 vuoden ikään asti alle 0,5 IU/L ja pojilla 11 vuoden ikään asti alle 1,0 IU/L, 
kun taas ylimmät U-FSH-arvot ovat tytöillä 10 vuoden ja pojilla 12 vuoden ikään asti 
alle 3,0 IU/L. U-LH-pitoisuuden mediaani oli esipuberteettivaiheessa tytöillä noin 0,06 ja 
pojilla noin 0,07. Poikien arvo kasvoi 11 vuoden ikään mennessä 10-kertaiseksi, 12 vuoden 
ikään mennessä 40-kertaiseksi ja 13–14 vuoden ikään mennessä 50-kertaiseksi. U-LH-
pitoisuuden mediaani kasvoi 5 ja 15 ikävuoden välillä kaikkiaan 75-kertaiseksi ja Tannerin 
asteesta G1 asteeseen G5 siirryttäessä 35-kertaiseksi. Tytöillä arvo kasvoi 11 vuoden ikään 
mennessä 30-kertaiseksi, 12 vuoden ikään mennessä 70-kertaiseksi ja 14 vuoden ikään 
mennessä 90-kertaiseksi. U-LH-pitoisuuden mediaani kasvoi 5 ja 15 ikävuoden välillä 
kaikkiaan 90-kertaiseksi ja Tannerin asteesta B1 asteeseen B5 siirryttäessä 40-kertaiseksi. 
Nämä havainnot osoittavat selvästi, että kliinisesti esipuberteettivaiheessa olevien lasten 
aamuvirtsanäytteen LH-pitoisuudet ilmentävät jo puberteettivaiheen tasoa. U-FSH-
pitoisuuksien muutokset iän myötä olivat pojilla ja tytöillä hyvin samanlaiset. Ainut ero oli, 
että tytöillä pitoisuudet olivat yleensä suuremmat varsinkin 2–8 vuoden iässä. Kummankin 
sukupuolen arvot viisinkertaistuivat puberteetin loppuun mennessä. Aamuvirtsan 
LH, FSH ja niiden suhteet korreloivat hyvin vastaavien lähtötasolla saatujen ja GnRH-
stimulaatiokokeessa saatujen seerumiarvojen kanssa (P < 0,001). Virtsan ja seerumin 
LH- ja FSH-pitoisuuksien ROC-käyrän (receiver operating characteristic) analyysi osoitti, 
että varhainen puberteetti (Tanner 2) pystyttiin erottamaan esipuberteetista (Tanner 
1) yhtä hyvin aamuvirtsan LH-arvojen ja U-LH/U-FSH-suhteen kuin GnRH-testin 
perusteella [käyrän alla oleva pinta-ala (AUC) 0,768–0,890 / 0,712–0,858]. Aamuvirtsan 
LH ja U-LH/U-FSH ennustivat pubertaalisen GnRH-testin tulosta yhtä hyvin kuin 
S-LH (AUC 0,90–0,93). Tutkituista testeistä vain aamuvirtsan LH erotti muutoksen 
Tannerin asteesta 1 asteeseen 2 yhtä hyvin kuin muutoksen asteesta 2 asteeseen 3 (p < 
0,001 pojilla ja p = 0,003 tytöillä), ja sekin osoittaa, että aamuvirtsan LH on luotettavin 
keino arvioida puberteettikehitystä. Siksi aamuvirtsan LH-määritystä voidaan käyttää 
puberteettikehityksen alustavaan diagnostiseen arviointiin, mikä vähentää kajoavan S-LH-
mittauksen ja GnRH-stimulaatiokokeiden tarvetta.
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5INTRODUCTION
Determinations of urinary gonadotropin levels have been used to evaluate gonadotropin 
secretion in children since the 1960s. Initially, bioassays (Fitschen & Clayton, 1965) were 
used. In the 1970s, Kulin and co-workers used radioimmunoassay (RIA) to measure FSH 
and LH in timed 3- to 24-h urine collections obtained from healthy infants and children 
and from patients with disorders of sexual maturation (Kulin, Bell, Santen, & Ferber, 1975; 
Kulin & Santner, 1977). In order to quantify the low concentrations in prepubertal children, 
they concentrated the gonadotropins by aceton precipitation of timed urine samples. Th eir 
study showed that the amount of U-LH excreted by prepubertal children was about 3% of 
the amount excreted by adults and of U-FSH about 9% (Kulin & Santner, 1977). 
Until the 1990s, the RIA methods were not sensitive enough to measure gonadotropin 
concentrations in biological samples obtained from prepubertal children unless the 
samples were extracted and concentrated (Rifk ind, Kulin, Rayford, Cargille, & Ross, 1970; 
Kulin et al., 1975; Kulin & Santner, 1977; Apter, Pakarinen, & Vihko, 1978; Bourguignon, 
Vanderschueren-Lodeweyckx, Reuter, Vrindts-Gevaert, Gerard, & Franchimont, 1980; 
Girard & Hadziselimovic, 1987; Maesaka, Suwa, Tachibana, & Kikuchi, 1990b; a). S-LH 
and S-FSH concentrations measured by RIA showed 2- to 6-fold increases during pubertal 
development, but their concentrations overlapped signifi cantly by pubertal stage, which 
rendered the evaluation of pubertal progress based on these assays, in fact, impossible 
(Faiman & Winter, 1974; Apter et al., 1978; Sizonenko, 1978). Development of ultrasensitive 
immunoassays based on time-resolved fl uorometry made it possible to determine the low 
prepubertal gonadotropin concentrations in serum and urine (Apter, Cacciatore, Alft han, 
& Stenman, 1989; Dunkel, Alft han, Stenman, & Perheentupa, 1990a; Dunkel, Alft han, 
Stenman, Tapanainen, & Perheentupa, 1990b; Wu, Butler, Kelnar, Stirling, & Huhtaniemi, 
1991; Dunkel, Alft han, Stenman, Selstam, Rosberg, & Albertsson, 1992; Goji & Tanikaze, 
1992). Th ese assays were then used to show that a rapid increase in daytime serum LH 
(S-LH) levels from below 0.2 IU/L to more than 0.5 IU/L (biochemical puberty) goes hand 
in hand with the emergence of the clinical signs of female puberty at around age 10-11 
(clinical puberty). 
Th e onset of pubertal maturation is initiated by gonadotrope activation characterized by 
increased pulse amplitude and frequency with higher bursts of LH than of FSH secretion 
during night-time (Jakacki, Kelch, Sauder, Lloyd, Hopwood, & Marshall, 1982). Th is is an 
amplifi cation of an existing circadian pattern of gonadotropin secretion. Th us, it is possible 
to evaluate pubertal development by taking samples at 10-20 min intervals for several hours 
during sleep (Apter et al., 1989; Apter, Butzow, Laughlin, & Yen, 1993; Manasco, Umbach, 
Muly, Godwin, Negro-Vilar, Culler, & Underwood, 1995). However, for practical reasons, 
this approach is of limited use.
Basal S-LH concentrations are superior to basal S-FSH concentrations for refl ecting the 
course of pubertal development. For instance, in girls, the increase in S-LH concentrations 
from the prepubertal level to the adult level is 50-100-fold; the corresponding increase in 
S-FSH is only 10-fold (Apter et al., 1989). 
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6Because the low basal LH and FSH levels in prepubertal children could not be measured 
practically by the available RIA methods until late 1980s, the higher gonadotropin 
concentrations produced by gonadotropin releasing hormone (GnRH) in the stimulation test 
have been used to evaluate gonadotropin secretion and pubertal development. Th e GnRH test 
has been the gold standard for evaluation of hypothalamic-pituitary-gonadal (HPG) function 
in pubertal disorders for over 40 years (Kastin, Schally, Gual, & Arimura, 1972; Kastin, Schally, 
Schalch, Korenman, Miller, Gual, & Perez-Pasten, 1972). However, the GnRH stimulation 
tests are invasive, involve adequately trained personnel for repeated blood sampling in hospital 
facilities and require several FSH and LH measurements. Th is results in high costs. Several 
research groups have aimed at simplifying the test, e.g., by simply determining S-LH in a 
single blood sample drawn at a selected time point (Cavallo, Richards, Busey, & Michaels, 
1995; Kandemir, Demirbilek, Ozon, Gonc, & Alikasifoglu, 2011; Kim, Kee, Seo, Yang, Chae, & 
Kim, 2011), but this approach has not become clinically established.
Information on integrated gonadotropin secretion can be obtained by measuring 
gonadotropins in urine samples collected over a certain period of time. Maesaka and 
colleagues have shown that urinary gonadotropin concentrations measured in monthly urine 
samples from patients with idiopathic precocious puberty follow a similar pattern as in healthy 
subjects matched for pubertal stage (Maesaka et al., 1990a).
An alternative to night-time blood collections (which refl ect the nocturnal increase in 
gonadotropin secretion) is to use fi rst-morning-voided (FMV) urine.
In the studies in this thesis, we have investigated whether FMV urine could be used to 
evaluate physiological and disturbed pubertal development, provided that the gonadotropin 
concentrations in FMV urine really refl ect the concentrations in serum and provide 
meaningful information about the secretion of LH and FSH.
Introduc? on
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1.1 Gonadotropins
1.1.1 Structure and function of gonadotropins
Th e gonadotropins which regulate pubertal development are luteinizing hormone or 
lutropin (LH) and follicle stimulating hormone or follitropin (FSH). Th ese hormones are 
secreted by the gonadotropes, which compose 7% - 15% of the cells in the anterior pituitary 
(Marshall, 2001). Both gonadotropins are synthesized and secreted in a pulsatile fashion 
in response to the pulsatile release of GnRH (Clarke & Cummins, 1982), an oligopeptide 
of hypothalamic origin, into the portal venous system of the pituitary gland. Pituitary 
gonadotrope activity and GnRH secretion are regulated by negative feedback governed 
mainly by gonadal steroids. In addition, inhibin B, produced by Sertoli cells within 
seminiferous tubules in males and ovarian granulosa cells in females, inhibits FSH secretion 
from the pituitary and thus controls separately the serum concentrations of LH and FSH. 
Activin, on the other hand, exerts an opposite eff ect and stimulates FSH biosynthesis and 
release from the gonadotropes of the pituitary gland (Ying, 1987).
LH and FSH are heterodimeric glycoproteins composed of two noncovalently bound 
dissimilar subunits, α and β (Shome & Parlow, 1973; Ward, Reichert, Liu, Nahm, Hsia, 
Lamkin, & Jones, 1973; Shome & Parlow, 1974a; b; Sairam & Manjunath, 1983; Ryan, 
Keutmann, Charlesworth, McCormick, Milius, Calvo, & Vutyavanich, 1987). Th e smaller 
α-subunit consists of 92 amino acid residues and is common to the glycoprotein hormone 
family: LH, FSH, human chorionic gonadotropin (hCG) and thyroid stimulating hormone 
(TSH). Th e β-subunits have diff erent amino acid sequences; this facilitates receptor-specifi c 
binding and activity of the intact heterodimer. Due to the diff erences in the amino acid 
sequence specifi c antibodies to each hormone may be generated (Pierce, Bahl, Cornell, 
& Swaminathan, 1971; Rathnam & Saxena, 1971; Vaitukaitis & Ross, 1974; Pierce & 
Parsons, 1981). Th e β-subunits of human FSH and LH contain 117 and 121 amino acids, 
respectively (Gharib, Wierman, Shupnik, & Chin, 1990). Th e β-subunits have an identical 
amino acid sequence within the family of glycoprotein hormones, but there is a 15 to 45 
per cent variation in carbohydrate composition and content (Vaitukaitis & Ross, 1974). Th e 
subunits with a higher content of carbohydrate (in particular, sialic acid) residues have a 
lower rate of metabolism and thus a longer half-life in the circulation. Th e relatively slow 
clearance rate of FSH (half-life 3-4 h) compared to LH (half-life 20 min) is attributed to the 
relatively higher content of sialic acid of FSH (de Leeuw, Mulders, Voortman, Rombout, 
Damm, & Kloosterboer, 1996). Th e half-life of hCG, which presents with a highly sialylated 
molecular structure, is the longest (24 h) among the glycoprotein hormones. Th e presence 
of terminal sialic residues and/or sulfated sugars provides protection of the hormone against 
degradation in the circulation. Treatment of glycoprotein hormones with neuraminidase 
(sialidase) shortens their circulatory half-life. Interestingly, sialylated recombinant LH and 
sulfated LH isolated from urine have the same half-lives (le Cotonnec, Loumaye, Porchet, 
Beltrami, & Munafo, 1998). 
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8Bioactivity and the net molecular charge of the gonadotropins are aff ected by variations in 
the N-linked carbohydrate side chains of the β-subunit (Haavisto, Pettersson, Bergendahl, 
Virkamaki, & Huhtaniemi, 1995; Huhtaniemi, 2000). Th e pituitary gonadotropin molecules 
comprise diff erently glycosylated ‘isoforms’, the compositions of which vary according to 
the physiological state. Th e biological potencies depend on the variation in the composition 
of the carbohydrate moieties (Jeff coate, 1993; Lambert, Talbot, Anobile, & Robertson, 1998) 
which changes during puberty (Phillips, Albertsson-Wikland, Eriksson, & Wide, 1997).
Synthesis of gonadotropin β-subunits is determined by the pattern of the GnRH pulse 
frequency. Slower GnRH pulses favor FSH synthesis and release, while faster pulses 
favor LH synthesis and release (Filicori, Santoro, Merriam, & Crowley, 1986; Shupnik, 
1990; Haisenleder, Dalkin, Ortolano, Marshall, & Shupnik, 1991; Burger, Dalkin, Aylor, 
Haisenleder, & Marshall, 2002). Receptor binding requires that the αβ-dimers are intact 
(Ryan et al., 1987). Gonadotropin secretion is further regulated by positive and negative 
feedback mechanisms (Figure 1). 
FSH exerts its eff ects by binding to a specifi c receptor on the membrane of its target 
cells, the follicular (granulosa) cells in the ovary and the Sertoli cells in the testis. Th e 
metabolic eff ects and stimulation of steroid secretion are induced by activation of adenylate 
cyclase and increased cAMP production (Knecht, Amsterdam, & Catt, 1981), which are 
eventually translated to follicular growth and preparation of the follicle for the ovulation-
inducing action of LH in the ovaries. FSH induces biosynthesis and secretion of estrogens 
(mainly estradiol) by facilitating aromatization of androgens, which are produced in the 
theca cells under the infl uence of LH, into estradiol 17β (Armstrong & Papkoff , 1976; 
Leung & Armstrong, 1980). FSH receptors are present only in the follicular cells of the 
ovary. On the other hand, LH receptors are found in the theca, interstitial and luteal cells, 
and to varying degrees also in follicular cells (Richards, 1980). In the male, FSH acts on 
the Sertoli cells and induces synthesis of an androgen-binding protein that appears to 
be involved in transporting testosterone to the seminiferous tubules and epididymis. 
Th is is essential for spermatogenesis which requires the presence of high local levels of 
testosterone (Means, Dedman, Tash, Tindall, van Sickle, & Welsh, 1980). FSH stimulates 
the growth of seminiferous tubules, which facilitates the initiation of spermatogenesis. A 
lack of FSH causes testis atrophy and cessation of sperm production. FSH also stimulates 
estradiol production in isolated Sertoli cells, but the importance of this for male physiology 
is unclear. In males, FSH and testosterone mediate the maturation of the Sertoli cells and 
the development of the functions that contribute to the initiation and maintenance of 
spermatogenesis. Spermatogenesis is promoted by testosterone, whereas meiotic division 
and formation of late spermatids to spermatozoa require FSH stimulation. However, 
maintenance of spermatogenesis, once initiated, does not necessarily require FSH 
(Depenbusch, von Eckardstein, Simoni, & Nieschlag, 2002). 
LH expresses its biological eff ect by binding to membrane receptors in the target organs, 
which activates adenylate cyclase and augments cAMP formation (Marsh, 1975; Dufau, 
Tsuruhara, Horner, Podesta, & Catt, 1977; Dufau, 1988). cAMP formed by LH receptor 
induction mediates the action of LH. It converts acetate to squalene (the precursor for 
Review of the Literature
9cholesterol synthesis) (Morris & Gorski, 1973) and cholesterol to 2α-hydroxycholesterol 
(Conti, 2002), and facilitates the use of circulating LDL-cholesterol for steroid synthesis 
(Hu, Zhang, Shen, & Azhar, 2010). All these steps are essentials for the formation of ovarian 
and testicular sex steroids. 
Figure 1. Regulation of the hypothalamic-pituitary-gonadal axis. Neural systems regulate 
gonadotropin-releasing hormone (GnRH) secretion and gonadal steroid hormones provide 
feed-back at the level of the hypothalamus and pituitary. CNS, central nervous system; CRH, 
corticotropin-releasing hormone; FSH, follicle-stimulating hormone; GABA, γ-aminobutyric 
acid; GALP, galanin-like peptide; LH, luteinizing hormone; NE, norepinephrine; NPY, 
neuropeptide Y. (From Williams textbook of endocrinology, 2011—12th ed. ISBN: 978-1-4377-
0324-5 / Shlomo Melmed et al.) Reproduced with permission from the author. 
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In males, the main function of LH is to stimulate production of testosterone in the Leydig 
cells of the testes, which promotes spermatogenesis together with FSH. In females, LH 
increases the production of androgens and androgen precursors, e.g., androstenedione, 
dehydroepiandrosterone and testosterone by stimulating the theca cells. Occupancy of a 
rather small portion of the LH receptors of the Leydig cells produces a full steroidogenic 
response (Huhtaniemi, Clayton, & Catt, 1982). Th e presence of an excess of (unoccupied) 
LH receptors on the corpus luteum or Leydig cell surface may therefore enhance the 
sensitivity of the cellular responses to low gonadotropin concentrations (Catt & Dufau, 
1973). 
1.1.2 Structure of FSH and LH in the pituitary, plasma and urine
Characterization of immunoreactive FSH by gel fi ltration and electrophoresis revealed no 
signifi cant diff erences between FSH in pituitary extracts, serum and urine (Maff ezzoli, 
Kaplan, & Chrambach, 1972; Talas, Midgley, & Jaff e, 1973). Th ese studies showed also that 
renal fi ltration did not damage the structure of the FSH molecule. Also the immunoreactive 
FSH peaks were the same regardless of the source of the urine sample, be it postmenopausal 
women, men or children (Maff ezzoli et al., 1972; Beitins, Derfel, O’Loughlin, & McArthur, 
1977).
Characterization of LH in urinary extracts by gel infi ltration revealed several 
immunoreactive peaks detected by RIA. In addition to the expected molecular weight 
range, peaks with lower molecular weights were identifi ed especially in urine. Th is indicates 
that subunits or fragments are formed as serum LH breaks down during renal excretion 
(Young, Harsoulis, Kuku, & Fraser, 1975). Th ese breakdown products can be detected only 
by some LH assays (Kovalevskaya, Birken, O’Connor, Schlatterer, Maydelman, & Canfi eld, 
1995).
1.1.3 Determination of gonadotropins
Development of methodologies for gonadotropin determinations
Th e fi rst methods for determination of hormones were bioassays. In vivo biological assays 
were employed for the fi rst time in the 1930s (Evans, Meyer, Pencharz, & Simpson, 1932). 
Th e result was quantifi ed by the biological response (e.g., ovarian, uterine or prostate 
growth) in test animals. However, test results were oft en inconsistent, since there were 
variations in sample extraction procedures and in the responses of the test animals. 
Many studies from the 1950s and 1960s concluded that gonadotropins are not detectable 
by bioassays in the urine of prepubertal children (Albert, 1956; Johnsen, 1959; Rosemberg, 
1960; Wilkins, 1965). Th e presence of gonadotropins in prepubertal children was even 
considered unphysiological (Johnsen, 1959), but some studies since the 1940s indicated 
that gonadotropins are indeed present in the urine also before puberty (Catchpole & 
Greulich, 1943; Brown, 1958; Fitschen & Clayton, 1965). Nevertheless, until the mid-1960s 
it was generally believed that prepubertal children did not have detectable gonadotropin 
concentrations in urine or plasma. 
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Th e fi rst RIA was developed by Yalow and Berson in 1959 (Yalow & Berson, 1959), aft er 
which bioassays were gradually replaced by immunoassays. Th is revolutionized research 
as well as the clinical practice of endocrinology. Decades later some authors still argued 
that concurrent utilization of in vitro bioassays and immunoassays is advantageous (Wide 
& Hobson, 1983), but immunoassays have become the dominating method for clinical 
diagnostics. 
Th e fi rst immunoassay for LH developed by Wide at al. was based on agglutination 
inhibition and antigen-coated red blood cells (Wide & Gemzell, 1962). In this assay, LH 
cross-reacts with hCG. Th e fi rst radioimmunoassay of LH that was sensitive enough for 
determination of LH in serum and urine without concentration of the samples was published 
in 1966 (Midgley, 1966; Odell, Ross, & Rayford, 1966). Th ese assays were based on the use 
of radiolabeled hCG as a tracer and anti-hCG antibodies which reacted equally with LH. 
Odell et al. reported that LH is detectable by RIA in the serum of children older than 1 year 
(Odell et al., 1966). Th is observation generated further studies on urinary assays. When 
large volumes of urine were used, it was possible to detect bioassayable concentrations of 
total gonadotropins (Kulin, Rifk ind, Ross, & Odell, 1967), including LH and FSH, in the 
urine of prepubertal children (Rifk ind, Kulin, & Ross, 1967; Kulin, Rifk ind, & Ross, 1968). 
Th e presence of gonadotropins in prepubertal urine was confi rmed by bioassays and RIAs 
(Fitschen & Clayton, 1965; Kulin et al., 1967) (Bagshawe, Wilde, & Orr, 1966).
In 1969, Wide et al. described the so-called sandwich assay. Th is is basically a diff erent 
assay principle based on the detection of “reagins” with an allergen bound to a solid phase 
and a labeled “antireagin” for detection (Wide, Bennich, & Johansson, 1967; Wide, 1969).
In 1970, Rifk ind et al. quantifi ed urinary FSH and LH by RIA (Rifk ind et al., 1970). Methods 
that involved extraction and concentration were later used to improve sensitivity, and 
timed urine samples were used for better accuracy (Kulin et al., 1975). Th e gonadotropin 
concentrations in prepubertal urine remained, however, below the detection limits of RIA 
despite extraction and concentration. In addition, non-specifi c interference may have 
overestimated the concentrations of RIA-detectable gonadotropin concentrations in serum 
(Apter et al., 1989; Chappel, 1990; Haavisto, Dunkel, Pettersson, & Huhtaniemi, 1990; 
Jaakkola, Ding, Kellokumpu-Lehtinen, Valavaara, Martikainen, Tapanainen, Ronnberg, & 
Huhtaniemi, 1990; Huhtaniemi, Ding, Tähtelä, & Välimäki, 1992).
Total gonadotropin excretion over 24 hours has been determined by assessment of FSH 
and LH in urine samples collected over 24 hours or shorter times (Kulin et al., 1975; Kulin 
& Santner, 1977; Santen & Kulin, 1986). In 1980, Bourguignon et al. showed that there is 
a morning increase in gonadotropin secretion at the time of onset of puberty. Th ey also 
showed that gonadotropin excretion follows a circadian pattern by analysis of unextracted 
urine samples collected as timed fractions of 24-h urine (Bourguignon et al., 1980). Girard 
et al. proposed the use of FMV urine as an alternative to the 24-h output, because the 24-h 
urine collection procedure is cumbersome and may be unreliable in children (Girard, 
Baumann, & Ruch, 1980). A study by Girard and Hadziselimovic advocated urinary 
gonadotropin determinations in FMV urine for diagnosis and treatment follow-up of 
various pubertal disorders. Th ey also employed extraction methods on urine samples for 
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increasing the sensitivity of the assay (Girard & Hadziselimovic, 1987). Maesaka et al., who 
used polyclonal double antibody RIA for analysis of urine samples extracted by ammonium 
sulfate, reported a high correlation between gonadotropin concentrations measured in 
FMV and 24-h urine (Maesaka et al., 1990b).
From the 1970s to the 1990s, radioimmunoassay was widely used use for determining 
LH and other glycoprotein hormones. However, this methodology had some limitations. 
RIA used antigens and antibodies labeled with radioactive isotopes with short half-lives. 
Highly specifi c antibodies were also a prerequisite, which was particular challenging for 
specifi c determinations of hCG and LH. In addition, the pulsatile secretion of FSH and LH 
complicated interpretation of the results of single samples (Santen & Bardin, 1973; Smith, 
Tcholakian, Chowdhury, & Steinberger, 1974). No less than 18 samples over a 6-hour 
interval or pooling of three blood samples obtained at 20-min intervals were proposed by 
various investigators for obtaining more reliable results (Santen & Bardin, 1973; Goldzieher, 
Dozier, Smith, & Steinberger, 1976).
RIA was the dominating method for hormone determination until the beginning of the 
1990s, but alternatives were being developed in the 1970s: enzyme immunoassays. Before 
that, Catt and Tregear showed that antibodies adsorbed to the wall of plastic tubes could 
bind antigens (Catt & Tregear, 1967). Th e use of such solid phase antibodies simplifi ed 
RIAs. Labeling of antibodies with enzymes was used for immunohistochemistry in 1969 
(Avrameas, 1969). A similar approach was taken for serologic assays in 1971 by Engvall 
et al., who called the method ELISA, enzyme-linked immunosorbent assay. ELISA was 
based on coating plastic with antigens or antibodies to produce a solid phase (Engvall & 
Perlmann, 1971). Subsequently, immunoassay has been facilitated by development of 
monoclonal antibodies (Kohler & Milstein, 1975) and highly sensitive non-radioactive 
labeling techniques (Ekins, Edwards, Jackson, & Geiseler, 1984). 
In 1968, Miles and Hales introduced sandwich assays with one antibody adsorbed to 
a solid phase and another radiolabeled antibody recognizing a diff erent epitope for 
detection (Miles & Hales, 1968). Th e introduction of sandwich assays (also called two-site 
immunometric assays) improved the detection 10- to 100-fold. A further improvement in 
assay sensitivity was achieved with the use of time-resolved fl uorometry for labeling the 
tracer antibody (Soini & Hemmila, 1979; Soini & Kojola, 1983; Ekins et al., 1984).
Assays for LH and FSH by dissociation-enhanced lanthanide fl uorescent immunoassay 
(DELFIA) were made commercially available by LKB Wallac. Th is technique provided 
high sensitivity (Lovgren, Hemmila, Pettersson, Eskola, & Bertoft , 1984; Bador, Dechaud, 
Claustrat, & Desuzinges, 1987). Th e assay is based on a sandwich technique in which two 
monoclonal antibodies are directed against two separate sites on the gonadotropin molecule 
(Lovgren et al., 1984). In contrast to polyclonal RIAs, this method allows measurement of 
intact molecules, and even isolated subunits as a supplementary feature. Also, very small 
sample volumes (25 μL) are suffi  cient for running immunofl uorometric assays (IFMAs) 
in contrast to the larger volumes (100-250 μL) required for RIAs. Th e reaction kinetics 
allows for a broad calibration curve and a wide range of sample concentrations without a 
need for dilution. In 1990s, the DELFIA LH assay came in two formats which varied with 
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respect to the duration of the incubation time, the regular LH assay and the so-called LH 
Spec assay. Many studies (Dunkel et al., 1990a; Dunkel et al., 1992; Kletter, Padmanabhan, 
Foster, Brown, Kelch, & Beitins, 1993b; Saketos, Sharma, Adel, Raghuwanshi, & Santoro, 
1994) used the DELFIA LH assay which required a 2-h initial incubation time. A potential 
limitation of this assay was the high degree of cross-reactivity with hCG, which was 
fortunately not an issue in pediatric endocrinology. Th is problem was eliminated with the 
introduction of the LH Spec assay (Pettersson, Ding, & Huhtaniemi, 1991; Taylor, Khoury, 
& Crowley, 1994). 
In the 1980s, two-site immunometric assays for gonadotropins with signifi cantly improved 
sensitivities were described (Stenman, Alft han, Myllynen, & Seppala, 1983; Lovgren et al., 
1984; Odell & Griffi  n, 1987). Th e use of monoclonal antibodies improved discrimination 
between LH and hCG (Pettersson, Siitari, Hemmila, Soini, Lovgren, Hanninen, Tanner, 
& Stenman, 1983; Soos & Siddle, 1983; Haavisto, Pettersson, Bergendahl, Perheentupa, 
Roser, & Huhtaniemi, 1993). With an assay using time resolved fl uorescence for detection, 
Apter et al., showed that the prepubertal LH concentrations of girls are very low and oft en 
undetectable (Apter et al., 1989). Th is indicated that previously reported LH measurements, 
which were based on competitive RIAs, overestimated LH (Wennink, Delemarre-van de 
Waal, van Kessel, Mulder, Foster, & Schoemaker, 1988; De Hertogh, Wolter, Van Vliet, & 
Vankrieken, 1989). Stenman et al. showed that this method could also be used on urine 
samples (Stenman, Alft han, Koskimies, Seppala, Pettersson, & Lovgren, 1985). Pettersson 
et al. also reported that radioimmunoassays overestimate the true LH concentrations 
either due to non-specifi c artifacts (matrix eff ects) or to cross-reactivity with free alpha 
subunits (Pettersson & Soderholm, 1991), which are present in both serum and urine 
(Prentice & Ryan, 1975; Ishibashi, Yamaji, Takaku, Teramoto, & Fukushima, 1987; Silva 
de Sa, Matthews, & Rebar, 1988; Landy, Schneyer, Whitcomb, & Crowley, 1990). Th is 
led to a critical evaluation of the validity of the results obtained with the fi rst-generation 
immunoassays (Chappel, 1990; Jaakkola et al., 1990). 
Haavisto et al. compared LH assay results obtained by an in vitro bioassay, a conventional 
RIA and an IFMA in their abilities to discriminate between CDPG and HH (Haavisto et 
al., 1990). Th e bioassay and IFMA aft er GnRH stimulation provided signifi cant distinction 
between CDPG and HH, whereas the RIA failed. Th e correlation of LH levels detected 
by bioassay was higher with IFMA than RIA, which apparently was due overestimation 
of low LH levels because of limited sensitivity and cross-reaction with free LH subunits. 
Using diff erent antibodies, Lövgren had developed two IFMA methods (Lovgren et al., 
1984), one which detected intact LH, the other intact LH as well as the free LH β-subunit. 
Th e correlation of LH levels measured by the two IFMAs in serum samples was excellent 
(Haavisto et al., 1990; Pettersson & Soderholm, 1990). Th is fi nding showed that serum does 
not contain any substantial concentrations of free LH β-subunits. Th e LH levels obtained by 
IFMA correlated highly also with those obtained by an in vitro bioassay but not with those 
obtained by conventional RIA (Haavisto et al., 1990). However, the ratio of bioactivity to 
immunoreactivity measured by RIA increased on GnRH stimulation and during normal 
pubertal development, whereas the ratio of bioactivity to immunoreactivity measured by 
IFMA under the same conditions remained the same (Haavisto et al., 1990).
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When ultrasensitive time-resolved IFMA was used to determine S-LH and S-FSH, the 
levels were low but detectable in serum samples obtained from prepubertal girls (Apter et 
al., 1989). Gonadotropin IFMAs have been successfully used to determine very low S-FSH 
and S-LH levels (Apter et al., 1989; Dunkel et al., 1990a; Dunkel et al., 1990b; Haavisto et al., 
1990; Wu et al., 1991; Dunkel et al., 1992; Goji & Tanikaze, 1992). Children at early pubertal 
stages have higher serum gonadotropin concentrations than children prepuberty; however, 
these concentrations are still much lower than those in adults (Apter et al., 1989; Dunkel 
et al., 1992; Bordini, Littlejohn, & Rosenfi eld, 2009; Mortensen, Ehrmann, Littlejohn, & 
Rosenfi eld, 2009; Zimmer, Ehrmann, & Rosenfi eld, 2010). RIAs were not sensitive enough 
for evaluation of prepubertal gonadotropin secretion. Since the beginning of the 1990s, 
highly sensitive immunofl uorometric and chemiluminometric assays have been routinely 
used for clinical research and practice. IFMA has been used to examine the pulsatile nature 
of gonadotropin secretion in healthy and hypogonadal prepubertal boys with primary 
testicular failure (Dunkel et al., 1990a).
Assessment of pubertal hormone concentrations requires consideration of diurnal and cyclic 
changes. Gonadotropin concentrations determined in clinically pubertal subjects during 
daytime may not catch the increase during the early stages of puberty because of cyclic 
and diurnal variations. Th e GnRH test was therefore the method of choice for evaluation 
of pubertal development (Cavallo & Zhou, 1994) and the diagnosis of pubertal disorders. 
An S-LHmax level greater than 4.0 IU/L aft er GnRH or GnRH-agonist administration has 
been regarded as the sign of evoked puberty (Carel, Eugster, Rogol, Ghizzoni, Palmert, 
Antoniazzi, Berenbaum, Bourguignon, Chrousos, Coste, Deal, de Vries, Foster, Heger, 
Holland, Jahnukainen, Juul, Kaplowitz, Lahlou, Lee, Lee, Merke, Neely, Oostdijk, Phillip, 
Rosenfi eld, Shulman, Styne, Tauber, & Wit, 2009; Bordini, Littlejohn, & Rosenfi eld, 2010).
1.2 Clinical aspects of puberty
1.2.1 Hormonal development during healthy puberty
Maturation of the HPG axis triggers the development of puberty in healthy children 
(Grumbach, 1975). Gonadal function matures during a period starting with sexual 
diff erentiation and development of the HPG system. Th is starts during the prenatal 
period and continues during infancy (Grumbach & Kaplan, 1974; Kaplan, Grumbach, & 
Aubert, 1976; Kaplan & Grumbach, 1978; Grumbach & Gluckman, 1994). It continues 
through a juvenile pause followed by maturation of the HPG axis during puberty (Reiter 
& Grumbach, 1982; Grumbach & Kaplan, 1990) (Figures 2 and 3). Increasing kisspeptin 
secretion induced by hypothalamic GPR54 signaling leads to secretion of GnRH (Shahab, 
Mastronardi, Seminara, Crowley, Ojeda, & Plant, 2005). GnRH-secreting neurons 
are activated by kisspeptin either indirectly via interneurons or directly by acting on 
gonadotropes (Han, Gottsch, Lee, Popa, Smith, Jakawich, Clift on, Steiner, & Herbison, 
2005; Messager, Chatzidaki, Ma, Hendrick, Zahn, Dixon, Th resher, Malinge, Lomet, 
Carlton, Colledge, Caraty, & Aparicio, 2005; Nazian, 2006). 
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Fetal life
Th e fetal pituitary gland contains FSH and LH by 10 weeks from conception. Gonadotropin 
secretion begins at 11-12 weeks. Th e gonadotropin content of the pituitary gland increases 
at 25-29 weeks (Grumbach & Kaplan, 1974; Kaplan et al., 1976; Kaplan & Grumbach, 1978; 
Grumbach & Gluckman, 1994; Grumbach, 2005). Fetal S-LH and S-FSH concentrations 
reach maximum levels at midgestation and decrease gradually until term. As the negative 
feedback system and sex steroid receptors in the hypothalamic-pituitary axis develop, 
serum FSH and LH concentrations of the fetus decrease towards term (Grumbach & 
Kaplan, 1974; Kaplan et al., 1976; Gluckman, Marti-Henneberg, Kaplan, & Grumbach, 
1983). Additionally, inhibin B plays a secondary role in suppressing FSH levels (Grumbach 
& Gluckman, 1994; Grumbach, 2005). Activin A, detectable in fetal serum samples, 
has not been shown to be involved with any endocrine change. Female fetuses have a 
higher pituitary content of gonadotropins, in particular during the fi rst half of gestation 
(Kaplan et al, 1976; Huhtaniemi, 1989) and a higher serum concentration of LH and FSH 
(Reyes, Winter, & Faiman, 1973) than their male counterparts. Th is is due to the negative 
feedback eff ects of fetal testicular hormones on LH and FSH. At midgestation, S-LH and 
S-FSH concentrations in female fetuses increase markedly and reach the same levels as 
postmenopausal women or agonadal adults. Th e FSH concentrations exceed those of LH 
in female fetuses, whereas the opposite is true for male fetuses (Takagi, Yoshida, Tsubata, 
Ozaki, Fujii, Nomura, & Sawada, 1977; Debieve, Beerlandt, Hubinont, & Th omas, 2000). 
Towards term, FSH and LH concentrations decrease and become almost undetectable due 
to inhibition by placental estrogens (Beck-Peccoz, Padmanabhan, Baggiani, Cortelazzi, 
Buscaglia, Medri, Marconi, Pardi, & Beitins, 1991);(Debieve et al., 2000).
Figure 2. Th ree periods of hypothalamic-pituitary axis activity. During fetal life, the activity 
peaks at midgestation and diminishes towards term, probably due to suppression induced 
by placental hormones and especially by estrogens. At birth, gonadotropin concentrations 
are low, but the hypothalamic-pituitary axis becomes active again at about 1 week aft er birth. 
Th is neonatal gonadotropin surge, or minipuberty, leads to activation of gonadal hormone 
secretion in both sexes. Th e activity peaks when the infant is 1–3 months of age, whereaft er the 
hypothalamic-pituitary activity gradually decreases and remains low until reactivation when it 
is time for the onset of puberty. Reprinted by permission from (Kuiri-Hanninen et al, 2014). © 
Horm Res Paediatr 2014, Copyright Clearance Center, License ID: 3645570771359.
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Early infancy - minipuberty 
In both sexes, high levels of placental estrogens cause low S-FSH and S-LH concentrations 
in cord blood due to the inhibition involved. Interestingly, the S-LH concentration in 
peripheral blood increases abruptly (about 10-fold) right aft er birth in the male newborn 
but not in the female. Th is LH burst occurs within a few minutes aft er birth and raises 
the serum testosterone levels during the fi rst 3 hours of postnatal life. Th e levels remain 
high for about half a day (Corbier, Dehennin, Castanier, Mebazaa, Edwards, & Roffi  , 1990; 
Grumbach & Kaplan, 1990; Kuiri-Hanninen, Sankilampi, & Dunkel, 2014). 
A hypothalamic GnRH pulse generator is clearly active by postnatal day 12. During the 
fi rst postnatal days, S-LH and S-FSH concentrations are low in both sexes (Winter, Faiman, 
Hobson, Prasad, & Reyes, 1975; Debieve et al., 2000) because hormones of placental origin 
are eliminated from the circulation in relation to their half-lives (Bidlingmaier, Wagner-
Barnack, Butenandt, & Knorr, 1973; Winter et al., 1975). S-FSH and S-LH concentrations 
rise during the fi rst postnatal week and peak in children aged 1–12 weeks (Winter et 
al., 1975; Andersson, Toppari, Haavisto, Petersen, Simell, Simell, & Skakkebaek, 1998; 
Bergada, Milani, Bedecarras, Andreone, Ropelato, Gottlieb, Bergada, Campo, & Rey, 2006; 
Kuiri-Hanninen, Kallio, Seuri, Tyrvainen, Liakka, Tapanainen, Sankilampi, & Dunkel, 
2011a; Kuiri-Hanninen, Seuri, Tyrvainen, Turpeinen, Hamalainen, Stenman, Dunkel, 
& Sankilampi, 2011b). Th is neonatal-to-midinfancy surge of pulsatile gonadotropin 
secretion (as well as of sex hormones and inhibin production) is due to an increase in the 
GnRH pulse amplitude and presents as a period of ‘minipuberty’, which may cause vague 
clinical symptoms [reviewed in (Kuiri-Hanninen et al., 2014)]. During these early weeks 
and months of life, S-LH predominates in boys and S-FSH in girls (Shinkawa, Furuhashi, 
Fukaya, Suzuki, Kono, & Tachibana, 1983; Andersson et al., 1998; Ibanez, Valls, Cols, Ferrer, 
Marcos, & De Zegher, 2002; Bergada et al., 2006). Th e mean S-LH levels are higher in boys 
than in girls (Kuiri-Hanninen et al., 2014), while the mean S-FSH levels are higher in girls 
than in boys during the newborn period and the fi rst few years of life (Kuiri-Hanninen et 
al., 2014). Th e S-LH concentrations in both sexes and S-FSH concentrations in girls decline 
aft er age 6–9 months, but high concentrations of S-FSH prevail in girls for a longer period 
of time–from an average of age 18 months to an average of 4 age years (Winter et al., 1975; 
Andersson et al., 1998; Kuiri-Hanninen et al., 2011a; Kuiri-Hanninen et al., 2011b).
Juvenile pause
When boys are approximately 6 months and girls 2–3 years, serum gonadotropin 
concentrations decrease to low levels that persist until the HPG axis becomes activated 
and chemical puberty ensues. During the juvenile pause, the hypothalamic GnRH pulse 
generator is relatively but not completely silent, since it produces low amplitude and low 
frequency GnRH discharges (Grumbach, 1978; Reiter & Grumbach, 1982; Apter et al., 
1989; Grumbach & Kaplan, 1990; Apter et al., 1993; Yen, Apter, Butzow, & Laughlin, 1993; 
Grumbach & Gluckman, 1994; Terasawa & Fernandez, 2001; Plant, 2008).
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Figure 3. Model of puberty timing control in primates. Th e role of kisspeptin (KP, green) 
signaling is thought be critical for the neural machinery and essential for generation of pulsatile 
GnRH (red) secretion in the hypothalamus. Th e GnRH pulse generator resides in the arcuate 
nucleus (ARC) and the signaling is relayed to GnRH terminals in the median eminence (ME) 
by KP projections arising from the perikarya in the ARC. During infancy (left  panel), the GnRH 
pulse generating activity in the ARC leads to intermittent release of KP in the ME and then to 
the release of GnRH into the portal circulation. Th is drives pulsatile secretion of LH and FSH. 
During transition from infancy to the juvenile phase of development (middle panel), a central 
inhibition (neurobiological brake) controls the ARC GnRH pulse generating mechanism 
and suppresses the pulsatile release of KP in the ME. Reduced GnRH release leads to a 
hypogonadotropic state in the juvenile period. Puberty is triggered when the neurobiological 
brake is removed and GnRH pulse generation and intermittent release of KP in the ME is 
reactivated (right panel). In this model, the secret of primate puberty lies in the nature of the 
neurobiological brake, i.e., the timing of its function during infancy and its release at the end of 
the juvenile period. Th e thickness of the blue (T, testosterone) and amber (E, estradiol) arrows 
indicate negative feedback by the testis and ovary, respectively, and refl ect the degree of gonadal 
steroid inhibition exerted on LH secretion during the three stages of primate development. AC, 
anterior commissure; AP, anterior pituitary gland, ARC, arcuate nucleus; OC, optic chiasm; ME, 
median eminence; MMB, mamillary body. Modifi ed from (Terasawa, Guerriero, & Plant, 2013). 
© Adv Exp Med Biol. 2013, Copyright Clearance Center, License ID: 3645431490581.
Highly sensitive and specifi c assays have been used to detect LH and FSH pulses with low 
amplitudes throughout the juvenile pause, during which the activity of the GnRH pulse 
generator is low (Kelch & Marshall, 1990; Apter et al., 1993; Yen et al., 1993; Mitsushima, 
Hei, & Terasawa, 1994; Mitsushima, Marzban, Luchansky, Burich, Keen, Durning, Golos, 
& Terasawa, 1996; Wu, Butler, Kelnar, Huhtaniemi, & Veldhuis, 1996; Albertsson-Wikland, 
Rosberg, Lannering, Dunkel, Selstam, & Norjavaara, 1997; Terasawa & Fernandez, 2001). 
GnRH stimulation causes only a modest response in prepubertal children except in infancy; 
this response becomes stronger as puberty approaches, is high during puberty (Grumbach, 
Roth, & Kaplan, 1974; Grumbach & Kaplan, 1990) and increases during adulthood (Keye 
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& Jaff e, 1975; Yen, Lasley, Wang, Leblanc, & Siler, 1975). Ultrasensitive LH and FSH assays 
(Apter et al., 1993; Albertsson-Wikland et al., 1997; Mitamura, Yano, Suzuki, Ito, Makita, 
& Okuno, 1999; 2000) have been used to confi rm the existence of pulsatile gonadotropin 
secretion in prepuberty and indicate that the basal levels of LH are much lower than 
previously reported (Mitamura et al., 1999; 2000). Th us, a functional GnRH defi ciency 
appears to regulate the hormonal status in prepubertal children (Grumbach et al., 1974; 
Reiter & Grumbach, 1982; Watanabe & Terasawa, 1989; Grumbach & Kaplan, 1990). An 
increased amplitude of LH and FSH secretion bursts appears at night-time in prepubertal 
boys and girls by 5 years of age. Th ere are LH pulses that occur mainly aft er falling asleep 
but not before slow-wave sleep begins (Shaw, Butler, McKinney, Nelson, Ellenbogen, & Hall, 
2012). Th is type of sleep is known as deep sleep, and, taken together, these observations 
indicate that deep sleep is closely associated with triggering of the GnRH pulse generator. 
Th e amplitude and frequency of these secretion peaks increase with the progression of 
pubertal development (Apter et al., 1989; Apter, 1993; Mitamura et al., 1999; 2000). 
Th e main factor inhibiting pubertal development during the juvenile pause between 
age 4 and 11 years appears to be a GnRH pulse generator inhibiting process, which is 
not associated with any steroid hormone (Grumbach et al., 1974; Grumbach & Kaplan, 
1988; Grumbach & Kaplan, 1990; Terasawa & Fernandez, 2001; Plant, 2008). Progressive 
impairment of this mechanism awakens the GnRH pulse generator as puberty approaches 
and proceeds. 
Gonadotropins (FSH rather than LH) are secreted in high amounts in infants with primary 
hypogonadism (e.g., Turner syndrome) and in prepubertal children, which indicates that 
a rather sensitive negative feedback mechanism restrains secretion of LH and FSH even 
when low levels of steroid hormones are secreted from the gonads of healthy prepubertal 
children (Burr, Sizonenko, Kaplan, & Grumbach, 1970; Conte, Grumbach, Kaplan, & 
Reiter, 1980; Grumbach & Kaplan, 1990). Administration of gonadal steroids in small doses 
blocks entirely gonadotropin secretion in childhood, indicating that the impact of negative 
inhibition by gonadal steroids on the HPG axis is rather strong (approximately 6 to 15 
times stronger than in adults) (Kelch, Kaplan, & Ghumbach, 1973; Grumbach et al., 1974; 
Grumbach & Kaplan, 1990). 
Onset of puberty
S-FSH levels are higher than the S-LH levels in prepubertal children of both sexes (Kaplan 
et al., 1976), and higher amplitudes of LH pulses than of FSH during sleep is a phenomenon 
that is regarded as the strongest indicator of puberty onset. Activation of the slumbering 
(partially silent) GnRH pulse generator results in increasing serum concentrations of LH, 
which heralds the onset of puberty at the biochemical level (Wu et al., 1996). Initially, 
the inhibition of the hypothalamic GnRH pulse generator is gradually decreased and LH 
secretion during sleep increases in prepubertal boys and girls (Boyar, Rosenfeld, Kapen, 
Finkelstein, Roff warg, Weitzman, & Hellman, 1974). 
With the approach of puberty, pulsatile secretion of GnRH escalates in parallel with the 
increases in LH reserves and sensitivity of the pituitary to GnRH as the inhibition on 
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the hypothalamic GnRH pulse generator lift s (Germak & Knobil, 1990). Endogenous, 
increasing GnRH secretion at puberty primes the gonadotropes (Roth, Kelch, Kaplan, & 
Grumbach, 1972; Grumbach et al., 1974), which increases the sensitivity of the pituitary 
to endogenous GnRH (as in the case of enhanced release of LH at nighttime during the 
course of normal puberty) and to exogenous GnRH (as in the response to intravenous 
GnRH during the prepubertal period) (Boyar, Finkelstein, Roff warg, Kapen, Weitzman, 
& Hellman, 1972; Job, Garnier, Chaussain, & Milhaud, 1972; Roth et al., 1972; Boyar, 
Finkelstein, David, Roff warg, Kapen, Weitzman, & Hellman, 1973; Roth, Grumbach, & 
Kaplan, 1973; Boyar et al., 1974; Kapen, Boyar, Freeman, Frantz, Hellman, & Weitzman, 
1975; Kelch, Clemens, Markovs, Westhoff , & Hawkins, 1975; Mitamura et al., 2000; Styne & 
Grumbach, 2002). Alternating rounds of disinhibition and reactivation of GnRH secretion 
occur before full-blown pubertal development gets established (reactivation episodes 
mainly during night towards late prepuberty) (Conte, Grumbach, & Kaplan, 1975; Conte 
et al., 1980; Reiter & Grumbach, 1982; Grumbach & Kaplan, 1990; Terasawa & Fernandez, 
2001; Plant, 2008). Th is increases the GnRH pulse amplitudes and causes pattern changes 
and a gradual increase in the LH pulses during the early hours of sleep as of the onset of 
puberty (Boyar et al., 1973; Judd, Parker, Siler, & Yen, 1974; Boyar, Wu, Roff warg, Kapen, 
Weitzman, Hellman, & Finkelstein, 1976; Wennink et al., 1988; Mitsushima et al., 1994; 
Mitsushima et al., 1996). Nocturnal LH secretion infl uences gonadal sex steroid secretion 
diff erently in boys and girls: peaks of estradiol occur during mid-day whereas peaks of 
testosterone occur almost instantly aft er sleep (Mitamura et al., 1999; 2000). Secretion of 
LH predominates during daytime as pubertal development gets established. Girls aft er 
menarche no longer present with this diurnal variation (Mitamura et al., 2000). Adult sex 
steroid concentrations, regulated by a moderate diurnal variation, are highest on awakening 
(Mitamura et al., 1999; 2000).
Later pubertal development
As puberty proceeds the amplitude and frequency of gonadotropin peaks escalate and 
daytime gonadotropin secretion increases (Boyar et al, 1972; Boyar et al, 1974; Dunkel et 
al, 1990a; Dunkel et al, 1990b; Hale et al, 1988; Hassing et al, 1990; Jakacki et al, 1982; 
Wennink et al, 1988). As increase in GnRH pulse frequency results in increased secretion 
of gonadotropins, favoring LH over FSH, which is one of the typical endocrine markers of 
pubertal development. Th is fi nding was confi rmed by the fi nding that the FSH/LH ratio 
increased as GnRH stimulation became less frequent (once per hour instead of one every 
3 hours) in adult rhesus monkeys with ablative hypothalamic lesions which eliminated the 
endogenous GnRH secretion (Wildt et al, 1981). 
During late prepubertal and pubertal periods, the increased amplitude, not the diff erence 
in pulse frequency, of the GnRH pulses increases gradually the LH pulses in both sexes 
(Mitamura et al, 1999; Mitamura et al, 2000; Wu et al, 1996). In other words, an increased 
serum LH response to GnRH is a fi nding associated with emerging puberty.
Th e main inhibitive mechanism limiting gonadotropin secretion in pubertal children 
appears to be the negative feedback exerted by gonadal steroids and inhibin, since primary 
hypogonadism raises serum gonadotropin concentrations (Plant, 2008). Both testosterone 
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and estradiol derived from aromatization of testosterone exert a negative feedback on the 
hypothalamus, and this suppresses pulsatile GnRH secretion (Pitteloud, Dwyer, DeCruz, 
Lee, Boepple, Crowley, & Hayes, 2008b; a). Aromatization of testosterone to estradiol is a 
prerequisite for testosterone to elicit negative feedback inhibition on pituitary LH and FSH 
secretion (Pitteloud et al., 2008b; a). Inhibin B is the main physiologic negative feedback 
regulator of FSH secretion, since suppression of FSH by estradiol is modest when inhibin 
B levels are in the normal range and becomes prominent only when inhibin B activity is 
absent, which is the case for men with anorchia or testes presenting with a non-functional 
seminiferous epithelium (Boepple, Hayes, Dwyer, Raivio, Lee, Crowley, & Pitteloud, 2008).
Central precocious puberty may occur when a prepubertal child has previously been 
exposed to excessive levels of androgens from an endogenous or exogenous source (e.g., 
aft er initiation of glucocorticoid therapy for congenital virilizing adrenal hyperplasia, or 
aft er removal of a sex steroid–secreting adrenal or gonadal neoplasm) (Reiter, Grumbach, 
Kaplan, & Conte, 1975). Most patients with a premature adrenarche, who secrete excessive 
amounts of adrenal androgens for their age, enter puberty and experience menarche in 
the same age as their unaff ected counterparts (Grumbach, 1977). Moreover, prepubertal 
children who present with low or absent adrenal androgen secretion as a result of chronic 
adrenal defi ciency have normal pubertal development, if they get adequate replacement 
therapy for the missing adrenal steroids (Grumbach, 1977). 
Cross-sectional and longitudinal studies have documented that an increase in serum 
concentrations of the precursors of adrenal androgens (dehydroepiandrosterone [DHEA], 
dehydroepiandrosterone sulfate (DHEAS) and androstenedione) precedes the rise in 
gonadotropin and gonadal steroid levels by approximately 2 years in both sexes. High 
levels of these precursors are maintained throughout puberty (Sizonenko & Paunier, 
1975; Grumbach, 1977; Reiter, Fuldauer, & Root, 1977) and they peak at age 20 to 30 
years, aft er which a gradual decrease takes place (Sklar, Kaplan, & Grumbach, 1980). 
Th e adrenarchal increase in DHEA and DHEAS secretion bears no association with the 
pituitary gonadotropes being more sensitive to GnRH stimulation (Reiter, Kaplan, Conte, 
& Grumbach, 1975) or with sleep-associated LH secretion; actually, this occurs usually at 
an age when the HPG axis function is the lowest (Grumbach, 1977). Th e signifi cance of the 
adrenarche for regulation of puberty is controversial. In addition to being a precursor for 
biologically active androgens (testosterone, dihydrotestosterone) and estrogens (estradiol) 
through peripheral conversion (Voutilainen & Jaaskelainen, 2015), DHEA is a neurosteroid, 
the concentrations of which increase as the cerebral cortex matures from age 6 years to the 
mid-20s. DHEA(S) plays an important role in the evolution of the adrenarche: it supports 
cortical development in the brain and facilitates memory functions which regulate social 
interaction outside the immediate family and acquaintances (Campbell, 2006).
1.2.2 Genetic basis: Neuroendocrine control of onset of puberty
Mutations in KISS1R gene encoding the receptor for kisspeptins, also known as GPR54 
cause hypothalamic hypogonadism (Seminara, Messager, Chatzidaki, Th resher, Acierno, 
Shagoury, Bo-Abbas, Kuohung, Schwinof, Hendrick, Zahn, Dixon, Kaiser, Slaugenhaupt, 
Gusella, O’Rahilly, Carlton, Crowley, Aparicio, & Colledge, 2003; Shahab et al., 2005). Th is 
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observation paved the way for further studies which then identifi ed several other genes, e.g., 
TAC3, TAC3R and LEPR, that regulate the onset of puberty (Sykiotis, Pitteloud, Seminara, 
Kaiser, & Crowley, 2010). Th ese genes are organized as functional webs that regulate the 
various steps which initiate the pubertal process.
Neurons secreting gonadotropin-releasing hormone (GnRH) are believed to be subjected 
to persistent trans-synaptic inhibition during the juvenile pause, which comes to an end as 
this inhibition expires. As expiration of inhibitory inputs alone cannot trigger the onset of 
puberty, an excitatory input to GnRH neurons is required. In fact, kisspeptin neurons are 
the major component of this excitatory input, as kisspeptin signaling is a prerequisite for the 
onset of puberty (Seminara et al., 2003). Pulsatile GnRH release in both sexes is triggered 
by activity of kisspeptin neurons of the arcuate nucleus (ARC) in the hypothalamus. Th e 
preovulatory surge of gonadotropins is dependent on kisspeptin neurons located in the 
anteroventral periventricular nucleus (AVPV) of the hypothalamus, which are almost 
absent from males (Pinilla, Aguilar, Dieguez, Millar, & Tena-Sempere, 2012).
Th e mechanism triggering the onset of puberty functions in a transcriptional model. An 
inhibition–activation model would be too simplistic because the network of genes involved 
in the pubertal onset mechanism facilitates the primary excitatory system (kisspeptin 
neurons) that controls pulsatile GnRH secretion. However, also an epigenetic regulation is 
known to be at least as essential and as eff ective (Lomniczi, Loche, Castellano, Ronnekleiv, 
Bosch, Kaidar, Knoll, Wright, Pfeifer, & Ojeda, 2013a). 
At the point when central puberty is initiated, promoter DNA methylation of Eed and 
Cbx7 genes takes place. Th is decreases the expression of these genes and increases the 
dissociation of their protein products from the Kiss1 promoter. Th is occurs in parallel with 
an increase in the expression of Kiss1 and changes in the chromatin status of the Kiss1 
promoter. Inhibition of DNA methylation counters the peripubertal decline in Eed and 
Cbx7 expression and blocks the removal of EED and CBX7 from the Kiss1 promoter, which 
arrests the onset of puberty (Lomniczi et al., 2013a).
Many cases of familial central precocious puberty are caused by mutations in the 
MKRN3 gene (Abreu, Dauber, Macedo, Noel, Brito, Gill, Cukier, Th ompson, Navarro, 
Gagliardi, Rodrigues, Kochi, Longui, Beckers, de Zegher, Montenegro, Mendonca, Carroll, 
Hirschhorn, Latronico, & Kaiser, 2013), a gene encoding transcriptional repressors. 
Th e decrease in hypothalamic expression of Mkrn3 in mice undergoing prepubertal 
development and MKRN3 defi ciency in patients with precocious puberty constitute 
fi rm evidence that MKRN3 represses the onset of puberty (Abreu et al., 2013). Th ese 
observations are supported by a longitudinal study by Hagen et al., who reported that 
serum MKRN3 concentrations decline prior to the onset of puberty and throughout 
puberty in healthy girls (Hagen, Sorensen, Mieritz, Johannsen, Almstrup, & Juul, 2015). 
Th e negative correlation between MKRN3 and gonadotropins in the same study further 
supports MKRN3 as a major regulator of hypothalamic GnRH secretion during childhood. 
Another supporting fi nding was that subjects with early onset of puberty have undetectable 
or low MKRN3 levels (Hagen et al., 2015).
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Th ese fi ndings demonstrate that genes from the zinc fi nger family regulate the timing of 
puberty onset through repression of downstream targets, rather than by activating GnRH 
neurons (Lomniczi, Wright, Castellano, Sonmez, & Ojeda, 2013b). Th ese fi ndings support 
the notion that the timing of puberty is regulated by transcriptional repression, rather than 
by some on-off  switch in the neuroendocrine circuitry (Lomniczi et al., 2013a). 
According to this new view on the central and peripheral mechanisms responsible for 
initiating puberty (Figure 4), the central control of puberty is provided by upstream 
mechanisms that involve gene silencing instead of inhibition occurring at the level of trans-
synaptic communication. 
Physiological (biochemical/neuroendocrine) onset of puberty before or along with the fi rst 
clinical signs of puberty should be evaluated closely by the clinician studying the start and 
development of puberty. Molecular genetic (neuroendocrine) regulation behind the initial 
activation and sustained activity of the HPG axis and GnRH pulse generator eventually 
establishes the nature of this unique physiological process.
Figure 4. Repressive control of puberty. In the ARC, two gene-silencing systems are involved–
the polycomb group complex and MKRN3. At the AVPV level, the completion of puberty is 
delayed by FGF21. Abbreviations: ARC, arcuate nucleus; AVP, vasopressin; AVPV, anteroventral 
periventricular nucleus; FGF21, fi broblast growth factor 21; MKRN3, makorin ring fi nger 
protein 3; SCN, suprachiasmatic nucleus; ZNFs, member of the zinc fi nger family of proteins. 
Reprinted by permission from (Ojeda & Lomniczi, 2014). © Nat. Rev. Endocrinol. 2014, Copyright 
Clearance Center, License ID: 3645741168018.
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1.2.3 Physical development during normal puberty
Th e onset of puberty in the Caucasian population occurs at age 9-14 years in boys and 
8-13 years in girls (Carel et al., 2009). Th e age at onset of puberty has decreased over the 
last 100 years (Parent, Teilmann, Juul, Skakkebaek, Toppari, & Bourguignon, 2003; Euling, 
Selevan, Pescovitz, & Skakkebaek, 2008; Biro, Galvez, Greenspan, Succop, Vangeepuram, 
Pinney, Teitelbaum, Windham, Kushi, & Wolff , 2010), but methodological issues hinder 
researchers from establishing whether this trend continues or not. Excess adiposity in girls 
may falsely be interpreted as a clinical sign of puberty onset, but there are studies suggesting 
that adiposity may facilitate, at least slightly, the onset of puberty in some girls (Rosenfi eld, 
Lipton, & Drum, 2009). 
Tanner staging, the gold standard for sexual maturity rating is an instrument for following 
a child’s advancement through puberty by physical examination. Breast (female) or genital 
(male) and pubic hair development are graded using separate stages. Pituitary gonadotropin 
and subsequent gonadal sex steroid secretion control male genital and female breast 
development, whereas adrenal and gonadal androgens regulate pubic hair development in 
both sexes (Reynolds, 1951; Marshall & Tanner, 1969; 1970; Herman-Giddens, Bourdony, 
Dowshen, & Reiter, 2010). Interestingly, there are reports that the increase in androgen 
levels occurs earlier in girls than in boys (Winter & Faiman, 1972; 1973), although this has 
not been confi rmed by later studies. Tanner stage 1 corresponds to the prepubertal status. 
Th elarche (Tanner stage B2) and testicular enlargement (Tanner stage G2) reveal that 
pubertal development has started (gonadarche) and will progresses to stage 3 through 5. 
Girls
Although breast budding is the usual sign heralding puberty, an increase in height velocity 
may also be an early marker for the onset of female puberty (Bourguignon, 1991). Early 
breast budding may be initially be unilateral for many months, which causes concern 
for both the subject and her parents. However, the situation is benign and transient. On 
the other hand, fat deposition (adipomastia) should not be confused with breast tissue 
development. Th e distinction is best made by careful examination of the subareolar 
region during palpation of the breast bud. Enlargement of the papilla of the nipple occurs 
continuously during pubertal development. Th e increase in the nipple diameter during 
breast stage 1 to 3 is quite small (3 to 4 mm) and becomes prominent only aft er breast stage 
3. Th is parameter provides an objective criterion to diff erentiate between stage 4 and stage 
5 (the fi nal diameter is approximately 9 mm) (Rohn, 1987). Th e timing of the menarche is 
usually closely associated with bone development, i.e., fusion of the second and fi rst distal 
phalanges and the appearance of the fi rst sesamoid of the thumb (Bjork & Helm, 1967). In 
most cases, this corresponds to Tanner breast stage 4. Th e 95th percentile for menarche is 
14.5 years, and a diagnosis of primary amenorrhea can be made if menses have not started 
at 16 years (Practice Committee of American Society for Reproductive Medicine, 2008).
Boys
Th e fi rst histologic sign of spermatogenesis occurs between ages 11 and 15 years. 
Spermaturia is indeed one of the fi rst signs of onset of puberty, but the presence of sperm 
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in the urine is periodic and therefore not a reliable indicator of puberty for all boys. 
Paradoxically, spermaturia is more common in early than in late puberty, which favors 
the argument that there may be a continuous fl ow of sperm through the urethra in early 
puberty, but that ejaculation is a prerequisite for sperm to appear in the urine in late puberty 
(Pedersen, Nysom, Jorgensen, Nielsen, Muller, Keiding, & Skakkebaek, 1993). Spermaturia 
in a FMV urine specimen appears at a median chronologic age of 14.1 years, and on average 
during pubic hair stage (Tanner PH) 2 to 3 (Schaefer, Marr, Seidel, Tilgen, & Scharer, 1990), 
but it has also been reported that spermaturia may occur in healthy, clinically prepubertal 
boys with bilateral testicular volumes of only 3 mL (Schaefer et al., 1990; Nysom, Pedersen, 
Jorgensen, Nielsen, Muller, Keiding, & Skakkebaek, 1994).
Testicular growth is the fi rst sign of puberty. Th is occurs on average 6 months later 
than initiation of breast development in girls (Bordini et al., 2009). Pubertal testicular 
enlargement is clinically evident when the length of the longitudinal axis of a testis is greater 
than 2.5 cm (excluding the epididymal tissue) or the testicular volume is greater than 3 mL 
(Van Vliet, 1991). In 1974, Zachmann et al. further developed the Prader orchidometer, a 
practical, rosary-like tool consisting of ellipsoids of increasing standardized volumes which 
correlate with the stage of puberty. Th e testicular volume index ([length × width of right 
testis + length × width of left  testis]/2) and testicular volume are measured by comparing 
the testes with the ellipsoids (Zachmann, Prader, Kind, Hafl iger, & Budliger, 1974; Taskinen, 
Taavitsainen, & Wikstrom, 1996). 
A longitudinal study by Biro et al. shows that puberty progresses within 6 months in 82% of 
boys with a testis volume of 3 mL, supporting the earlier fi nding by Staff ord et al. (Staff ord, 
Weir, Pearl, Imai, Schydlower, & Gregory, 1989; Biro, Lucky, Huster, & Morrison, 1995). 
Ultrasonography is a reliable method to determine testicular volume. However, testicular 
volumes measured by ultrasound are only about half of those determined by orchidometry, 
but the correlation between these measurements is quite strong (Goede, Hack, Sijstermans, 
van der Voort-Doedens, Van der Ploeg, Meij-de Vries, & Delemarre-van de Waal, 2011). 
S-LH concentrations keep rising as adult-type Leydig cells emerge and proliferate in the 
testes as pubertal development progresses. Leydig cell maturation seems to occur mainly 
during the three phases of increasing testosterone production, i.e., 14 to 18 weeks of fetal 
life, 2 to 3 months aft er birth, and puberty (Prince, 2001).
Most boys attain Tanner stage 3 level of pubic hair maturity within 1.0 to 1.5 years of the 
start of testicular growth (Tanner & Davies, 1985). Boys at Tanner genital stage 4 present 
with further masculinization and secondary sexual characteristics: facial hair and male 
type voice change. Asymmetric testicular development and gynecomastia (breast tissue 
development in boys) are normal variations of pubertal progression. Half of the boys have 
varying degrees of gynecomastia during pubertal development. It presents aft er Tanner 
stage G2 (predominantly during Tanner stage PH3 to 4) and persists rarely for more than 1 
year (Biro, Lucky, Huster, & Morrison, 1990). 
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Pubarche occurs as a result of increased production of androgens, which may be of adrenal 
or gonadal origin. Th erefore pubarche alone cannot be regarded as a defi nitive indicator of 
gonadal functionality. Tanner stage PH2 may be a sign of early sexual hair growth, but may 
also be caused by generalized hypertrichosis. Th us, Tanner stage PH3, i.e., the appearance 
of frank sexual hair, should be regarded as an accurate sign of pubertal development, rather 
than Tanner stage PH2. Th e pubertal changes of Tanner stage PH3 usually result from 
gonadal androgen production (Rosenfi eld et al., 2009), although the changes of Tanner 
stages PH2 through PH4 may also result exclusively from adrenal androgens. Th is is the 
case for both sexes, although the development of the male escutcheon (Tanner stage PH6), 
i.e., sexual hair extending along the linea alba from the pubic area, is explicitly related to an 
androgenic eff ect. 
A gradual deceleration of growth velocity occurs slightly before the onset of puberty 
(Tanner & Davies, 1985). With puberty the production of estrogens and androgens 
stimulates statural growth by facilitating the production of growth hormone via direct and 
indirect pathways.
Th e pubertal growth spurt is primarily related to pubertal stage, not chronological age. Th e 
female pubertal growth spurt occurs at Tanner breast stage 3, about 1 year before menarche 
and in males at Tanner genital stage 3 or 4, during which spermarche takes place (Marshall 
& Tanner, 1970; Nielsen, Skakkebaek, Richardson, Darling, Hunter, Jorgensen, Nielsen, 
Ingerslev, Keiding, & Muller, 1986). Th us, the pubertal growth spurt starts about two years 
later in boys than girls. Boys grow taller than girls because boys have a longer duration of 
prepubertal growth and a greater pubertal peak height velocity. 
1.2.4 Disorders of puberty
Delayed puberty and sexual infantilism
If a girl is prepubertal still at age 13 and a boy at age 14, it is prudent to evaluate clinically 
whether this constitutes normal variation of maturation or whether examinations are 
needed. A hypothalamic, pituitary or gonadal disorder is possible, if sexual maturation has 
not proceeded to its completion by 4.5 years aft er the onset of puberty in boys or if there is 
no menstruation 5 years aft er the onset of puberty in girls. 
LH and FSH concentrations are typically elevated in hypergonadotropic hypogonadism. 
On the other hand, diff erentiating between hypogonadotropic hypogonadism and 
constitutional delay of growth and puberty (CDGP) is challenging, because laboratory 
fi ndings, clinical signs and symptoms overlap. Th e concentrations of serum gonadotropins 
are low in both conditions. Most boys with pubertal delay are late variants in the onset 
of puberty and growth pace (CDGP) and the condition is transient. Th e laboratory 
studies required for the diff erential diagnosis are sensitive serum gonadotropin assays, a 
GnRH stimulation test to assess the degree of rise of the S-LH concentration and serum 
testosterone or estradiol.
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Idiopathic or constitutional delay in growth and puberty
CDGP is the most common form of delayed puberty, particularly in boys. CDGP refers 
to onset of puberty aft er age 13 in otherwise healthy girls and 14 in boys. Subjects with 
CDGP are oft en short in stature (>2 SD below the mean height for age) and present with a 
typical history of short stature for several years, although their growth velocity and height 
are usually in line with the expected bone age. Most of these adolescents have a family 
history of a mother or sister with delayed menarche or a father (or brother) with delayed 
puberty and a prolonged growth period extending beyond that of peers. Th is suggests 
that CDGP follows a familial pattern of genetic dominant inheritance with incomplete 
penetrance (Sedlmeyer, Hirschhorn, & Palmert, 2002; Sedlmeyer & Palmert, 2002). CDGP 
refers to physiologic immaturity and a slow pace of maturation; full sexual maturity will 
eventually be reached, but progression is slower than among peers. Since these children 
have a temporal lag in reactivation of their GnRH pulse generator and the HPG axis, they 
experience delays in pubertal maturation with reference to their chronologic age but not 
their physical growth. Children with CDGP present oft en with a lag in both adrenarche 
and gonadarche (Sedlmeyer & Palmert, 2002), whereas adrenarche usually occurs at the 
expected age in patients with isolated gonadotropin defi ciency (Sklar et al., 1980). In CDGP 
bone age is usually delayed at presentation and during pubertal development. 
Sexual precocity
Sexual precocity is the appearance of any clinical sign of puberty before 8 years in girls 
and 9 years in boys. Th ese are the lower reference age limits for the appearance of the fi rst 
clinical signs of puberty. Children with signs or symptoms of precocious puberty should, 
regardless of age, be evaluated with regard to central nervous system disorders and other 
serious diseases. Th e etiology is oft en idiopathic in girls and organic in boys (Sorensen, 
Mouritsen, Aksglaede, Hagen, Mogensen, & Juul, 2012). 
1.3   Clinical use of urinary gonadotropin measurements
General considerations 
Urine is a convenient medium for the assessment of many biomarkers, including the 
gonadotropins. Kidney function develops from birth throughout childhood in terms of 
the number of nephrons, the glomerular fi ltration rate (GFR) and tubular secretion and 
reabsorption. GFR values increase signifi cantly during the neonatal period and infancy 
(Chen, Aleksa, Woodland, Rieder, & Koren, 2006): the glomerular fi ltration rate (GFR) is 
2-4 ml per min per 1.73 m2 in term neonates, and it doubles within 1 week. Th is increase 
is due to an increased cardiac output and decreased renal vascular resistance. By the end 
of 1st year of life, GFR reaches adult values. However, it should be kept in mind that the 
GFR in relation to body surface area or body weight, even at this stage, is much higher in 1 
yr old infants than in adults (Chen et al., 2006). GFR continues to increase also aft er it has 
reached adult values until prepubescent age, and this results in a higher clearance rate of 
overall renal excretion in children compared to adults (Chen et al., 2006). Our fi ndings in 
regard to gonadotropin concentrations from serum and urine confi rm this observation: the 
median concentrations of LH in the urine were several fold compared to those in the serum 
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(I-III). Th is provides an additional advantage for the determination of gonadotropins 
which circulating in the blood at very low levels before the onset of biochemical puberty.
Th erefore, urine has been used as an alternative body fl uid for gonadotropin studies in 
children and adults for many years (Raiti, Light, & Blizzard, 1969; Baghdassarian, Guyda, 
Johanson, Migeon, & Blizzard, 1970; Girard & Hadziselimovic, 1987). Assays of urinary 
gonadotropins for pediatric studies and studies related to puberty were fi rst reported more 
than 60 years ago (Dorff , Appelman, & Liveson, 1948). Th ese assays were very laborious 
bioassays which required repeated urine collections and pretest processing procedures 
(Fitschen & Clayton, 1965; Rifk ind et al., 1967). When urine rather than serum is used, 
invasive procedures such as venipuncture are eliminated. Th is improves patient cooperation 
and compliance in the clinical setting as well as volunteer availability for research studies. 
Initially, pooled urine was collected for urinary gonadotropin analysis. Several samples 
from the same patient and from groups of several patients were pooled together (Kulin 
et al., 1967; Kulin et al., 1968). In some studies, pooling was performed by pubertal status 
(Reiter, Kulin, & Hamwood, 1973). 
Timed urine collection was previously the most common form of urine sample collection 
for urinary gonadotropin measurements, and the duration of urine collection varied greatly 
as shown in Table 1.
Single, non-timed urine samples (e.g., morning-time spot samples) were also used in 
several studies (Faiman & Ryan, 1967), but they did not refl ect the night-time hormonal 
activity (despite being taken in the morning). FMV urine samples based on accumulated 
urine from the time of retiring to that of waking refl ect the sleep-time HPG-axis activity 
and are the most commonly used method (Hansen & Ross, 1975; Kulin, Moore, & Santner, 
1976; Penny, Goldstein, & Frasier, 1976; Saketos et al., 1994; Maesaka, Tachibana, Adachi, 
& Okada, 1996). Random samples have again been used in some recent studies (McNeilly, 
Mason, Khanna, Galloway, & Ahmed, 2012; Singh, Jimenez, Newman, & Handelsman, 
2013). 
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Table 1. Various forms of timed urine collections for urinary gonadotropin measurements. 
VARIOUS TIMED URINARY SAMPLE 
COLLECTIONS STUDY (Author, Year)
3-hour urine collections  
before and after naloxone infusion Veldhuis, 1982
3-6 hour collections
Kulin, 1975; Kulin, 1979;  
Santner, 1981; Kulin, 1985;  
Kulin, 1994
3 to 9 hour collections Kulin, 1984
3 to 13 hour collections Kulin, 1976
3 to 24 hour collections Kulin, 1977
8-hour collections Beitins, 1976
3 times 3-hour collections  
(before, during and after GnRH infusion) Reiter, 1977
12-hour collections  
(some during the day, some during the night) Reiter, 1977
Wake-time (0800 h – retiring) and sleep-time 
(retiring - 0800 h) collections Chipman, 1981
Timed overnight collection Penny, 1978
3-hour urine samples collected  
for 24 hours and pooled Beitins, 1976
4-hour urine samples collected  
for 24 hours and pooled Bourguignon, 1980
The largest single pool: 24 hours
Kulin, 1967; Kulin, 1969;  
Stevens, 1969; Baghdassarian, 1970; 
Rifkind, 1970; Sciarra, 1970; Kulin, 1972; 
Reiter, 1973; Kulin, 1975; Beitins, 1976;  
Bourguignon, 1977; Bourguignon, 1980;  
Rettig, 1981; Chipman, 1981; Witchel, 1996
Urinary gonadotropins have been assayed directly after sampling in some studies (Kulin et al., 
1968), but often urine samples are stored under various conditions before assay (Table 2).
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Table 2. Various conditions of storing urine samples before gonadotropin assays.
VARIOUS STORAGE 
CONDITIONS  
for urinary samples
STUDY 
Author, Year
4 °C for “short term” Saketos, 1994
4 °C during collection period Rifkind, 1969
4 °C for two weeks Stevens, 1969
4 °C for 3 days Sciarra, 1970
4 °C for 1 to 8 weeks Bourguignon, 1977
4 °C for 1 month Maesaka, 1996
-16 °C for two weeks Rifkind, 1969
-16 °C for 12 to 14 months Rifkind, 1970
-20 °C for up to 1 week Rettig, 1981
-20 °C for 4 weeks Saketos, 1994
-20 °C for 3 to 6 months McNeilly, 2012
-20 °C for 4 years Singh, 2013
-20 °C simply indefinitely  
until assayed 
Stevens, 1969; Stevens, 1969;  
Faiman, 1967; Rettig, 1981;  
Bourguignon, 1980; Kulin, 1984;  
McNeilly, 2012; Buckler, 1970;  
Beitins, 1976; Beitins, 1976
In several studies on gonadotropins adjustment for the urinary flow rate has been made 
by correcting for the serum creatinine concentration (Hansen & Ross, 1975; Girard & 
Hadziselimovic, 1987; Maesaka et al., 1990a; Saketos et al., 1994; McNeilly et al., 2012). 
However, with the advent of highly sensitive assays, creatinine adjustment neither reduces 
day-to-day variability regardless of the gonadotropin concentrations nor improves the 
intrasubject correlation between concentrations in the urine and serum (Boeniger, Lowry, 
& Rosenberg, 1993). Singh et al. corrected the gonadotropin concentrations in urine to 
correspond to the specific gravity of 1.020 for gonadotropin assays in adult men (Singh et 
al., 2013). 
Variable proportions of FSH and LH are lost when urine is stored frozen at -20 °C and 
this can be prevented by adding glycerol to a concentration of 70 mL/L. This retains 
full gonadotropin immunoreactivity for almost one year (Saketos et al., 1994). In some 
studies, urine samples have been treated with urea (e.g., 6 mol/L) to dissociate the subunits 
(Saketos et al., 1994). Although the assays described in the study by Saketos et al. appear 
to measure intact glycoprotein hormones, some FSH immunoreactivity is retained 
after urea treatment (Saketos et al., 1994). (Saketos et al., 1994). This finding supports 
previous work and confirmed the protective role of glycerol, which stabilizes protein 
conformation by decreasing peptide-reaction sites for urea (Gekko & Timasheff, 1981). 
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Addition of albumin has also been used to preserve immunoreactivity (Livesey, Roud, 
Metcalf, & Donald, 1983; Saketos et al., 1994; Kesner, Knecht, & Krieg, 1995). Recovery 
was similar in glycerol and after acetone precipitation (Saketos et al., 1994). Preservation of 
urine samples with 70 mL/L glycerol and storage at -20 °C compares favorably with the more 
time-consuming method of acetone extraction (Livesey et al., 1983). Storage of urine at -20 
°C alone causes loss of gonadotropin (hCG) immunoreactivity (Lempiainen, Hotakainen, 
Alfthan, & Stenman, 2012). Because of the loss of LH and FSH in frozen and unpreserved 
urine, studies involving gonadotropin measurements in unpreserved specimens should 
be evaluated with caution. In some studies, urine samples have been preserved using 
merthiolate or chloroform (Buckler & Clayton, 1970), whereas no additives before storage 
at -20°C have been used in some other studies (McNeilly et al., 2012; Singh et al., 2013). No 
loss of gonadotropins was reported in these studies. 
Most of the early studies on urinary gonadotropins have used some form of sample 
pretreatment before assay. Kulin et al. concluded that radioimmunoassays of unprocessed 
urine do not provide adequate sensitivity, unlike immunoassay or bioassay of urine extracts 
(Kulin et al., 1968). Different pre-treatments have been used to concentrate the urine of 
prepubertal children enough to obtain detectable levels of gonadotropins. Many different 
concentration methods have been used, e.g., vacuum dialysis (Beitins, Derfel, O’Loughlin, 
& McArthur, 1976), kaolin-acetone extraction (Kulin et al., 1967; Rifkind et al., 1967; Kulin 
et al., 1968; Stevens, 1969), and acetone precipitation (Raiti & Blizzard, 1968; Baghdassarian 
et al., 1970; Santner, Santen, Kulin, & Demers, 1981; Kulin, Demers, Chinchilli, Martel, 
& Stevens, 1994; Saketos et al., 1994). In a comparative study, acetone was favored over 
kaolin-acetone extraction (Reiter et al., 1973). 
Acidification of the urine improves the efficiency of the precipitation. In some studies the pH 
was adjusted to 7 (Rettig, Duckett, Sweetland, Reiter, & Root, 1981). Further concentration 
of the protein precipitate may be achieved by lyophilization (Rifkind et al., 1967; Sciarra & 
Leone, 1970) or air drying (Baghdassarian et al., 1970; Santner et al., 1981; Saketos et al., 
1994). In most studies, the attained ratio of concentration was 20-fold compared to the 
unconcentrated urine sample (Kulin et al., 1976; Santner et al., 1981). 
In early bioassay studies, urinary samples had to be concentrated to compensate for poor 
gonadotropin assay sensitivity. Nor were RIA methods for urine samples sensitive enough 
to detect the sleep/wake differences in gonadotropin secretion during the late prepubertal 
period or the sleep-augmented LH surge during later stages of pubertal development 
(Chipman, Moore, Marks, Fevre, Segel, Ramsey, & Boyar, 1981). Recent studies have 
demonstrated that critical S-LH peak concentrations either during sleep or in response 
to GnRHag predict the onset of biochemical puberty in both sexes, more reliably in boys 
(Rosenfield, Bordini, & Yu, 2012; 2013).
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OBJECTIVES OF THE STUDY
1. To study if invasive serum determinations can be replaced by highly sensitive IFMAs 
for urinary FSH and LH measurements in children.
2. To determine the age-related course of gonadotropin concentrations from birth to 
post-puberty and defi ne age-specifi c reference values.
3. To evaluate FMV gonadotropin determinations as markers of imminent pubertal 
development and the transition from prepuberty to puberty.
4. To analyze the agreement between FMV urinary gonadotropin concentrations and 
GnRH stimulation test results for assessing pubertal development.
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SUBJECTS AND METHODS
2.1 Subjects, inclusion criteria and samples
Th e subjects, inclusion criteria and samples for studies I-IV are summarized in Table 3. 
Table 3. Subjects, inclusion criteria and samples.
DESCRIPTION STUDY I STUDY II STUDY III STUDY IV
Number of 
subjects (male/
female)
65 (43/22) 184 (102/82) 297 (145/152) 274 (196/78)
Age range (yr) 0-15and adults 0 - 18 5 - 17 5 - 17
Origin Finnish Finnish Danish Swedish
Health status
No disorders or 
medication
 aff ecting 
endocrine 
and/or kidney 
function
No disorders or 
medication
 aff ecting 
endocrine 
and/or kidney 
function
No disorders or 
medication
 aff ecting 
endocrine and/
or 
kidney function
Referred for 
investigation of 
growth 
or pubertal 
disorders
Sample Paired urine and serum Urine
Paired urine 
and serum
Paired urine 
and serum, 
GnRH test
Collection time 
and period
FMV
early morning 
from newborns
FMV
early morning 
from newborns
FMV FMV
Preservatives None, sodium azide or tymol None None None
Storage 20 °C, 4 °C and -20 °C 4 °C -20 °C 4 °C
Notes
No urine 
sample taken 
during 
menstruation
No urine 
sample taken 
during 
menstruation
No urine 
sample taken 
during 
menstruation;
for both sexes: 
blood samples 
in the same 
morning as 
urine
No urine 
sample taken 
during 
menstruation;
for both sexes: 
blood samples 
in the same 
morning as 
urine
Th e time for sample collection and storage was approximately one week before assaying (II-IV), 
except for the studies on the eff ect of storage temperature and time on the recovery of urinary 
gonadotropins (I). 
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2.2 Assay procedures
Polypropylene tubes were used for storage of urine in order to reduce adsorption of 
gonadotropins onto the tube wall. Th e additional value of coating the tube walls with 
bovine serum albumin (BSA) to reduce sticking of gonadotropins onto the tube walls was 
also studied. 1/3 fi lled tubes with 2 or 20 g/L of BSA in 0.9 % NaCl in phosphate buff er, 
pH 7.4 (Boehringer Ingelheim’s Fraction 5) were rotated overnight. Th e eff ects of sodium 
azide and thymol as preservatives were studied using concentrations of 1 g/L and 20 g/L, 
respectively.
FSH and LH concentrations in paired urine and serum samples were measured in 
duplicate by the DELFIA® IFMA (Stenman et al., 1985; Soini & Lövgren, 1987; Pettersson 
& Soderholm, 1990; Stenman, Alft han, & Turpeinen, 1991) using diagnostic kit reagents 
obtained from Wallac (Turku, Finland); slight alterations to the assay protocols were made. 
Th e assays are solid phase, two-site immunofl uorometric assays using two monoclonal 
antibodies directed against diff erent epitopes. Th e walls of microtiter wells were coated by 
immobilization of antibodies to the solid phase. Europium chelate was the tracer of choice 
for labeling the indicator antibody, specifi c for the alpha subunit. 
Th e assays were calibrated against the WHO Second International Standard for pituitary 
LH for immunoassay (80/552) and the Second International Reference Preparation of 
pituitary FSH/LH (78/549), respectively. Th e sample (25 μL) was diluted with 0.2 mL of 
assay buff er. 
Each assay followed a two-step procedure. Th e sample was brought into reaction with the 
immobilized capture antibody for 2 h (LH) or 3 h (FSH). Following the fi rst washing step, 
europium-labeled indicator antibody was added into the wells. Aft er incubation for 1 h and 
a subsequent (second) wash, enhancement solution was added to dissociate europium from 
the labeled antibody into the mixture, in which highly fl uorescent chelates were formed due 
to content of the enhancement solution. Th e quantity of gonadotropin in the sample was 
calculated in proportion to the intensity of the fl uorescence light, which was measured for 1 
s/sample in an Arcus 1230 fl uorometer (Wallac). 
Th e eff ect of correction for variations in urinary excretion on gonadotropin concentrations 
was studied using the following formulae [I]: 
Concentration corrected for creatinine = concentration/creatinine [IU/mol], or 
Concentration corrected for density = concentration x (0.02/(density-1) [IU/L].
U-FSH and U-LH concentrations were not corrected for variations in urine excretion 
rate (such as urinary density or creatinine), because their correlation with the respective 
serum levels did not improve. On the contrary, this correlation became poorer due to 
overcorrection with very dilute urine samples in some cases [I]. 
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Th e detection limit of the test was defi ned as the concentration indicating a mean 
fl uorescence of 12 zero standard repeats plus two standard deviations. Th e intra-assay and 
inter-assay coeffi  cients of variation (CV) were determined by assaying 20 aliquots of 3 
samples of varying concentrations. A CV <10% was regarded as acceptable. CVs were not 
calculated separately for low, medium and high concentrations, as the CV was recorded 
as a function of zero standard repeats, which have been taken as a reference point because 
especially the low concentration range was of clinical interest.
In study III, we determined S-estradiol and S-testosterone by RIA (Diagnostic Products 
Corp., Los Angeles, CA, USA and Immunodiagnostic System Ltd., Boldon, UK, 
respectively). Th e detection limit of the testosterone assay was 0.23 nmol/L and that of the 
estradiol assay 0.018 nmol/L (data from kit inserts). 
Two diff erent IFMAs were used to assay U-LH. Th e LH Delfi a detects only intact LH, 
whereas the LHspec Delfi a detects also ß-subunits and certain fragments of LH. Th e 
detection limit of the LHspec assay was 0.012 IU/L. Th e intra-assay and inter-assay CVs 
were 5.7 and 6.4%, respectively. 
2.3 Ethical considerations
Th e research protocol was approved by the Ethics Committee of the Children’s Hospital, 
Helsinki University Central Hospital. Where applicable, informed consent was obtained 
from the parents. For study III, the research protocol was also approved by the ethics 
committee of the Department of Growth and Reproduction, Copenhagen University. As for 
study IV, approval regarding the research protocol was obtained from the Ethics Committee 
at Sahlgrenska University Hospital, University of Gothenburg. 
2.4 Statistical analysis
Th e detection limit was based on the mean concentration of 12 repeat assays of the zero-
standard plus two standard deviations. Samples with concentrations of LH and FSH 
below the detection limit were assigned a value of 0.01 IU/L. Correlation and regression 
analyses were used to analyze the relationships between serum and urinary gonadotropin 
concentrations. Fisher’s r to z test was used to examine the statistical signifi cance of the 
correlation. Th e eff ects of sample volume (25 to 200 μL, keeping the total incubation volume 
at 225 μL) and incubation time (1 h to overnight) were studied. Statistical signifi cance was 
defi ned as a P value < 0.05.
Analysis of variance (ANOVA) was used to compare concentrations by age groups and the 
Student’s t test to compare the means between adjacent age groups and between the boys 
and girls in each age group.
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Th e non-parametric Kruskal-Wallis and the Mann-Whitney U Test were used to analyze 
diff erences in hormone concentrations between diff erent pubertal stages. 
Paired comparisons were performed using the Wilcoxon signed rank test. Th e increase 
in gonadotropin and steroid levels from early childhood (median level at 5 years) to late 
adolescence (median level at 15 years) and the basic pubertal increase from genital/breast 
stage 1 (median level at stage 1) to genital/breast stage 5 (median level at stage 5) were 
calculated.
Th e GnRH stimulation test result was classifi ed as pubertal if the maximal S-LH 
concentration (S-LHmax) was above 5 IU/L and the S-LHmax/S-FSHmax ratio above 1.0. 
Th is follows clinical practice at the Gothenburg Pediatric Growth Research Center (GP-
GRC). Regression and correlation analyses (Spearman’s test) were used to establish the 
correlation between gonadotropin concentrations and their ratios in FMV urine (U-FSH, 
U-LH, U-LH/U-FSH) and serum during the GnRH stimulation test (basal FSH = S-FSH, 
basal LH = S-LH, maximal FSH = FSHmax, maximal LH = LHmax, S-LHmax/S-FSHmax). 
Also, the correlations between pubertal stages (Tanner breast stage B, genital stage G, 
pubic hair stage PH, testicular volume) and the gonadotropin concentrations were studied. 
Receiver operating characteristics (ROC) curve analysis (Zweig & Campbell, 1993) was 
used to calculate the area under the curve (AUC), sensitivity and specifi city levels at various 
cut-off  values for the diff erentiation of prepubertal (Tanner B/G stage 1) from pubertal 
stages (Tanner B/G >2) and also separately to predict the results of the GnRH stimulation 
test.
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RESULTS 
3.1 Characterization of (urinary) gonadotropin assays
Detection limits
Th e detection limits of the FSH and LH assays were 0.018 IU/L and 0.015 IU/L, respectively. 
Th e intra-assay and inter-assay CVs ranged from 2.3% to 7.8% and 5.2% to 8.7%, 
respectively.
Eff ect of incubation time
Th e detection limits of 2-h, 3-h and overnight LH incubations were 0.015 IU/L, 0.018 IU/L 
and 0.023 IU/L, respectively, and the corresponding values for FSH were 0.020 IU/L, 0.018 
IU/L and 0.018 IU/L. An incubation time of 2 h for LH and 3 h for FSH provided the best 
level of sensitivity. Extending the incubation time overnight did not improve the sensitivity.
Eff ect of sample volume
When the urinary sample volume was increased from 25 μL to 225 μL, results were lower 
than expected (Figure 5).
Eff ect of storage temperature
Th e gonadotropin concentrations were stable when urinary samples was stored at 4 °C. By 
the end of seven weeks, 93.3% of the FSH and 95.1% of the LH was recovered. Storing 
of urine at -20 °C, at room temperature and performing 3 freeze-thaw cycles caused 
a signifi cant decrease in FSH (down to 76.9, 71.0, and 48.7%, respectively) and LH 
concentrations (down to 77.4, 43.8, and 47.3%, respectively) by the end of the study period 
for this experiment (7 weeks) (Figure 5).
Eff ect of coating sample tubes
Coating the inner walls of the tubes with various concentrations of BSA had no eff ect on 
recovery of FSH or LH from urine samples. 
Eff ect of additives
Recovery of FSH or LH in urine stored at 4 °C was not infl uenced by addition of sodium 
azide or thymol as preservatives and storage for up to 7 weeks.
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Figure 5. Eff ect of storage time and sample volume on three diff erent samples (left ), and 
storage time and temperature (right: -20 °C [?], 4 °C [?] and 20 °C [?]) on urinary LH 
concentrations. Modifi ed from study I. © Pediatric Research, Copyright Clearance Center, License 
ID: 3624381266914.
3.2 Correlation between urinary and serum gonadotropin 
concentrations 
Gonadotropin concentrations measured in paired urine and serum samples correlated very 
well. Th e correlation did not improve aft er corrections for variations in urinary fl ow rate. If 
the urine was very dilute (density ≤ 1.007), correction for urinary density and especially for 
creatinine impaired the correlation (Figure 6 and I). Gonadotropin concentrations in urine 
and serum of two girls with Turner syndrome correlated well also when gonadotropin 
concentrations were high (I). On the other hand, the concentrations of intact LH were 
invariably very low in all once frozen and thawed urine samples, and here the correlation 
between U-LH and S-LH was low, suggesting degradation of LH in the frozen and thawed 
urine samples (Figure 5, I and III).
Th e serum LH concentration correlated well with the FMV U-LH concentrations 
determined by the LHspec assay (r = 0.64, P<0.0001) (III). Th e median concentrations of 
LH in the urine were 1.1- to 5-fold compared to the concentrations in serum (III). Th e 
correlation between U-LH and S-LH levels was lower in children in early puberty (r = 0.44, 
P = 0.001 for boys and r = 0.44, P<0.0001 for girls) than in prepuberty and late puberty (r = 
0.83, P<0.0001 for boys and r = 0.78, P<0.0001 for girls) (III).
Th e FMV U-LH and U-FSH concentrations correlated well with the corresponding basal 
and GnRH-stimulated serum levels (P<0.001 for all) (IV). Th e ratios of FMV U-LH/U-FSH 
and S-LHmax/S-FSHmax correlated strongly (P<0.001 for both) (IV). U-LH and S-LH 
correlated strongly with pubertal stage (Tanner B, G) and testicular volume (P<0.001) (IV). 
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Figure 6. Eff ect of correcting or not correcting urinary LH concentrations for urinary density 
and creatinine concentration. Left : Density-corrected, Center: Uncorrected, Right: Creatinine-
corrected. Th e symbols refer to urine samples of diff erent densities (normal ? density = 1.008-
1.024, dilute u density ≤ 1.007 and concentrated s density ≥ 1.025). Modifi ed from study I. © 
Pediatric Research, Copyright Clearance Center, License ID: 3624381266914.
3.3 Gonadotropin concentrations in relation to age and 
pubertal stage
Th e age-related course of urinary gonadotropin concentrations is shown in Figures 7 
through 9 (detailed in II). Th e course of gonadotropin concentrations measured in paired 
urine and serum samples by age (during clinical prepuberty) and pubertal stage are shown 
depicted in Figure 8 (detailed in III).
Boys
Th e mean concentration of U-LH (about 1 IU/L) in newborn boys (less than 4 weeks old) 
was much higher than in any of the other prepubertal age groups (about 0.1 IU/L) (II). 
Th e relatively high concentrations encountered during infancy were followed by very low 
levels of U-LH at age 2-8 years (P<0.01 between 0-2 and 2-8 years) (II). Among Finnish 
boys aged 5–8 years had very low U-LH concentrations (median 0.06-0.07 IU/L) (III). Th e 
U-LH concentrations in boys started to increase from about 0.1 IU/L before age 8 years and 
reached a mean level of 1.0 IU/L by age 11 and 3.0 IU/L by age 12 years (P<0.01 between 
2-8 and 8-12 years) (II). In study III, the U-LH concentrations of Danish boys followed 
a very similar course: it started to increase from a median of 0.06-0.07 IU/L before age 9 
years and reached a median level of 0.6 IU/L by age 11, 2.4 IU/L by age 12 and 3.0 IU/L by 
age 13-14 years (III). By the end of pubertal development of Finnish boys, the mean U-LH 
concentration reached 5.0 IU/L (II), whereas the median U-LH concentration reached 4.64 
IU/L by the end of puberty in Danish boys (III). Th e increase in U-LH concentrations was 
statistically signifi cant already between age groups 7-8 and 9-10 years (III).
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Figure 7. Age-related course of U-LH (upper left  and upper right) and of the U-LH/U-FSH ratio 
(lower left  and lower right) in 184 healthy children. Modifi ed from study II. © Journal of Clinical 
Endocrinology and Metabolism, Copyright Clearance Center, License ID: 3624380909793.
Th e increase in gonadotropin concentrations during puberty was steep: there was 
75-fold increase in U-LH from age 5 to 15 years, and the overall increase in S-LH 
levels was 50-fold from early childhood to late adolescence. Th e diff erence between the 
median U-LH values during genital stages 1 and 5 was approximately 35-fold (III). 
Th e increase in U-LH preceded the increase in S-LH. Th e median S-LH concentrations 
reached 1.0 IU/L at around 12 years and 2.0 IU/L at 13-14 years. Th e initial rise in the 
U-LH concentrations by the age 9–10 was accompanied two years later by an increase 
in S-LH concentrations, as the increase in S-LH of boys between age 11 and age 12 
years became prominent and statistically signifi cant (III). Both the U-LH and the 
S-LH concentrations correlated with those of serum testosterone (r = 0.77, P<0.0001 
and r = 0.85, P<0.0001, respectively) (III). However, the increase in serum testosterone 
levels became signifi cant only one year later, i.e., aft er age 12 years. Th us, the increase 
in serum testosterone did not occur among clinically prepubertal children, not until 
transition to pubertal stage 2. 
Th e U-FSH concentrations of newborn boys were relatively high, the mean value was 
slightly above 1.0 IU/L. Th e U-FSH decreased to about 0.3 IU/L by the time the boys 
reached an age of 3 years. A gradual increase in U-FSH concentrations emerged aft er age 
5 years. Th e mean U-FSH concentrations increased about 5-fold during puberty (P<0.01 
from age 2-8 to age 8-12 years; P<0.05 from 8-12 to 12-18 years) (II).
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Figure 8. Distribution pattern of urinary and serum LH levels in children, all pubertal 
stages. Stage 1 subjects (prepubertal) were divided into 5 age groups. Th e lines in the boxes 
are median values (50th percentiles). Th e lower and upper limits of the boxes correspond to 
the 25th and 75th percentiles and the notches show the 10th and 90th percentiles. Outliers 
are shown separately. Asterisks denote statistically signifi cant diff erences between hormone 
levels in consecutive age groups or pubertal stages. * p<0.05, ** p<0.01, *** p<0.001, blank: 
not signifi cant. Modifi ed from study III. © Journal of Clinical Endocrinology and Metabolism, 
Copyright Clearance Center, License ID: 3624380909793.
Girls
During the neonatal period and infancy, the U-LH levels were similar for girls and boys. 
Aft er a signifi cant decrease following the neonatal period, the U-LH concentrations 
of Finnish girls remained below 0.5 IU/L until age 8 years (II). Th is low U-LH level was 
confi rmed in our subsequent study on Danish children, in which U-LH concentrations 
remained below 0.5 IU/L in girls until 8 years of age, with the exception of one case with a 
level of 0.8 IU/L (III). 
Th e mean U-LH concentration of 0.1 IU/L during prepuberty starts to increase aft er age 8 
years and reaches the mean pubertal concentration of 9 IU/L at age 14 (P<0.05 between 2-8 
and 8-12 years; P<0.0001 between 8-12 and 12-18 years), which corresponds to a 90-fold 
increase in U-LH during female pubertal development (II). 
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U-LH and serum estradiol concentrations started to increase at around age 9 years, 
preceding the rise in S-LH levels which start from age 11 years (III). Th e age-related course 
of U-LH during pubertal maturation followed an almost identical pattern in studies II and 
III; the median U-LH concentration increased approximately 90-fold from a prepubertal 
median level of 0.07 IU/L to 2.0 at 11 years, 5.0 IU/L at 12 years and 6.3 IU/L at 14 years 
(regardless of pubertal stage) (III). Th e increase in median U-LH from breast stage 1 to 5 
was only 40-fold (III).
Th e U-LH concentrations of girls were slightly higher than the corresponding S-LH 
concentrations and increased statistically signifi cantly at an earlier age than the S-LH. 
Among prepubertal girls, there was no signifi cant diff erence in S-LH concentrations by age 
group. Th e increase in S-LH levels from the early prepubertal median of 0.04 IU/L to the 
late pubertal median of 3.7 IU/L was approximately 90-fold. Th e increase in S-LH levels 
was also 90-fold from breast stage 1 to 5. 
Th e serum estradiol concentrations correlated strongly with the LH concentrations in both 
serum (r = 0.70, P<0.0001) and urine (r = 0.65, P<0.0001) samples. Th e rise in U-LH and 
serum estradiol concentrations, which took place at age 9–10 years, preceded the increase 
in S-LH levels by approximately 2 years (Fig. 1 in III). Unlike the boys, the S-LH levels 
of the girls rose signifi cantly only aft er the clinical signs of puberty were seen, not in any 
prepubertal age group (III).
Figure 9. Comparison of U-FSH 
concentrations and the U-LH/U-
FSH ratio in both sexes at diff erent 
age groups. Data is shown as the 
mean ± SEM. * p<0.05, ** p<0.001, 
*** p<0.0001 (sex diff erence 
within the age group). Modifi ed 
from study II. © Journal of Clinical 
Endocrinology and Metabolism, 
Copyright Clearance Center, 
License ID: 3624380909793.
Th e mean U-FSH levels of the girls followed an almost identical course as of the boys during 
childhood and puberty, but the girls did have somewhat higher U-FSH concentrations 
than the boys before age 8 years (II). Like the boys, the U-FSH concentrations of the girls 
increased 5-fold from prepubertal age to full puberty (P<0.001 between 8-12 and 12-18 
years) (II).
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LH/FSH ratio in both sexes
Th e U-LH/U-FSH ratio of newborns varied markedly. Th e mean was about 3.0 for newborn 
boys and decreased to the mean level of 0.1-0.3 by age 1-8 years, started to rise steeply 
at about age 12 years, reached temporarily a level of 2.0, and settled at about 1.0 in later 
puberty (II). 
Aft er the newborn period, the U-LH/U-FSH ratio of prepubertal girls remained, on 
average, below 0.1 (lower than for the boys) (Figure 9). Th e ratio started to increase sooner 
than among the boys, at age 9 years onwards, attained a level of 2.0 by age 14 years, and 
settled later at about 1.0, as for the boys (II). 
3.4 Urinary gonadotropins as an alternative to basal and 
GnRH-stimulated gonadotropins
Th e FMV U-LH and U-FSH concentrations correlated strongly with the corresponding basal 
and GnRH-stimulated S-LH and S-FSH levels (P<0.001). Th e FMV U-LH/U-FSH ratios also 
correlated strongly with the corresponding S-LHmax/S-FSHmax ratios (P<0.001). U-LH and 
S-LH correlated strongly with the pubertal stage (Tanner B, G) and testicular volume. Th e 
increase in FMV U-LH concentrations and U-LH/U-FSH ratios from prepuberty (Tanner 
stage B/G1) to the earliest pubertal stage (Tanner B/G2) was highly signifi cant (P<0.001 in 
boys and<0.01 in girls). Th ese increases were at least equally signifi cant as the corresponding 
increases in S-LH or S-LHmax concentrations and the S-LHmax/S-FSHmax ratios at this 
developmental stage (IV).
ROC curve analyses showed that for diff erentiation of clinically classifi ed pubertal and 
prepubertal stages the U-LH concentrations and U-LH/U-FSH ratios were at least as good 
as the S-LH and S-LHmax concentrations or the S-LH/S-FSH and S-LHmax/S-FSHmax 
ratios (Table 1, IV). Th e AUC-values were about 0.9 for all these parameters.
Among boys, the sensitivity to detect early puberty (Tanner G stage 2) by the GnRH test 
was 92% at a specifi city of 66%. With cut-off  values of 1.48 IU/L for U-LH and 0.05 IU/L 
for S-LH, equal sensitivity (92%) and specifi city (67%) were obtained. Among girls, the 
selected cut-off  limits for a pubertal GnRH-test result (detecting puberty Tanner B stage 2) 
gave a specifi city of 66% but a sensitivity of only 59%. At the same level of sensitivity (59%), 
a cut-off  level of 2.60 IU/L for U-LH and 0.17 for the U-LH/U-FSH ratio provided higher 
levels of specifi city (96% and 79%, respectively). Suitable cut-off  values to identify puberty 
with U-LH were 1.5 IU/L for boys and 1.2 IU/L for girls, and with S-LH 0.04 IU/L for boys 
and 0.02 IU/L for girls (IV).
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DISCUSSION
4.1 Methodological considerations of urinary gonadotropin 
determinations 
Th e choice of sampling for diagnostic tests is oft en challenging in pediatric practice, 
since invasive methods are particularly problematic. Urinary samples can be obtained by 
non-invasive, simple and inexpensive methods but not all analytes of clinical interest are 
excreted into urine. However, gonadotropins are present in urine at levels similar to those 
in the plasma. Interestingly, the fi rst gonadotropin bioassays were performed on urine 
samples (Rosemberg, Smith, & Dorfman, 1957; Rosemberg, 1960). Th ose studies showed 
that gonadotropin concentrations increase strongly during pubertal development, but the 
methods were too complicated for routine diagnostic use. Determination of gonadotropins 
for clinical diagnostics became feasible with the advent of RIA methods. Th e sensitivity 
of RIA made it possible to evaluate HPG function in adults, but the concentrations in the 
plasma of prepubertal children were below the detection limit of RIA methods. 
Th e development of sandwich assays in combination with monoclonal antibodies and 
highly sensitive labeling techniques made it possible to measure much lower hormone 
concentrations than with conventional RIAs. Th e combination of time-resolved fl uorometry 
and lanthanide labels made it possible to develop highly sensitive IFMA. Th ese methods for 
assessment of the concentrations of LH and FSH were about 100 times more sensitive than 
conventional RIA, and now the detection of the low prepubertal gonadotropin levels in 
serum and urine was substantially facilitated. Th e crucial step in eliminating nonspecifi c 
interference caused by variations in the composition of urine was the emergence of an assay 
which could be run on small sample volumes. IFMAs provided suffi  cient sensitivity with 
sample volumes of only 25 μL in a total volume of 225 μl per assay well (Stenman et al., 
1991). 
Conventional RIA methods overestimate LH in low levels, which is due to nonspecifi c 
interference caused by serum components (Stenman et al., 1991). Th us, ratios of bioactive 
to immunoreactive gonadotropin concentrations from earlier RIA-based studies had to be 
revised by further studies (Apter et al., 1989; Chappel, 1990; Haavisto et al., 1990; Jaakkola 
et al., 1990; Huhtaniemi et al., 1992). Two-site immunometric assays with high specifi city 
and sensitivity are currently considered the methods of choice for determination of very 
low concentrations of LH and FSH in the serum (Apter et al., 1989; Dunkel et al., 1990a; 
Dunkel et al., 1990b; Haavisto et al., 1990; Dunkel et al., 1992; Apter, 1993; Apter et al., 
1993; Kuiri-Hanninen et al., 2014, I-IV). 
Another challenge presented by urinary gonadotropin measurements is the possible 
underestimation of true concentrations due to degradation of gonadotropin molecules 
during excretion into urine, which leads to the formation of fragments such as LHß and 
LHcβf. Depending on the assay, these fragments may or may not be immunoreactive 
(Franchimont, Gaspard, Reuter, & Heynen, 1972; Young et al., 1975; Beitins et al., 1976; 
Neven, Iles, Howes, Sharma, Shepherd, Edwards, Collins, & Chard, 1993). We measured 
only intact LH and FSH but not their fragments, since the main methodology employed 
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in all our studies requires the presence of both alpha and beta subunits. However, in one 
of our earlier studies (III), we found that the U-LH concentrations determined from fresh 
samples by the LHspec kit which detects β-subunits and its fragments (in addition to intact 
LH molecules), were not statistically diff erent from those obtained with the LH assay 
measuring only intact LH (unpublished data). Th us, in our experience, fragmentation of 
LH does not seem to be a problem in children.
We studied modifi cations of the assay methods to further improve sensitivity of the standard 
method. Increasing the incubation time in the fi rst step from 1 to 2 or 3 h was useful (I). 
Th is is in line with an earlier study by Apter et al., who found that the detection limit for 
the LH assay improved slightly when an incubation time of 2 instead of 1 h was used (0.019 
IU/L) (Apter et al., 1989). Th e detection limits for 2-h, 3-h and overnight incubations for 
U-LH were 0.015, 0.018 and 0.023 IU/L, respectively. Th e optimal detection limit was thus 
obtained with an incubation time of 2 h. However, increasing the sample volume from 25 to 
50 μL or larger reduced recovery, apparently due to nonspecifi c interference by the sample 
matrix (Stenman et al., 1991) (I). 
Sample handling and storage turned out to be important. Urinary gonadotropins were found 
to be stable for several weeks when stored at refrigerator temperature, but freezing at -20 °C 
decreased gonadotropin concentrations in many samples. In addition, repeated freezing and 
thawing of urine samples caused sharp losses in the FSH and LH concentrations measured 
in the fresh samples (I). However, in previous studies using RIAs (Landy et al., 1990) and 
immunoenzymometric assays (Brindle, Miller, Shofer, Klein, Soules, & O’Connor, 2006), 
LH and FSH remained stable and measureable even aft er freezing and thawing. Th is may 
be explained by variable recognition of degradation products formed during freezing (and 
thawing) by diff erent assays.
Livesey et al. also reported that LH and FSH are unstable at -20 C. Th ey showed that 
glycerol can be used as a preservative during storage at -20 to -25 °C (Livesey et al., 1983). 
Aft er addition of glycerol (70 mL/L), urine samples can be stored at -20 °C (Saketos et al., 
1994) for long periods of time. Th is is useful for clinical follow-up as well as for longitudinal 
studies. However, glycerol is on the WADA (World Anti-Doping Agency) list of prohibited 
substances, which may prohibit its use for storage of urine samples for doping testing 
(Singh et al., 2013).
We have routinely stored urine samples without preservatives at +4 °C. Adding preservatives, 
such as sodium azide or thymol, did not bring any benefi t to the storage of urine samples at 
4 °C for up to 7 weeks in attempts to conserve the original LH and FSH concentrations in 
freshly assayed samples for even longer periods of time (I).
Coating of inner walls of the tubes with BSA prevents loss of growth hormone (GH) in 
urinary samples. Th is has been found useful for measuring GH in urine (Moreira-Andrés, 
Cañizo, & Hawkins, 1993), because the GH concentrations in urine are only about 0.01% 
of those in plasma (Baumann & Abramson, 1983). Coating of collection tubes with BSA 
did not improve the recovery of gonadotropins in urine (I), which may at least partly be 
explained by the relatively high gonadotropin concentrations in urine (comparable to those 
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in plasma). However, coating the inner walls of the tubes with diff erent dilutions of BSA 
did not aff ect the recovery of urinary gonadotropins disadvantageously (I). Th erefore, urine 
samples collected for any purpose can also be used for U-LH or U-FSH measurements, 
which should be kept in mind particularly for initial evaluation of growth and pubertal 
disorders.
Th e eff ect of urinary fl ow rate on urinary hormone concentrations is a potential 
confounder. Th is is oft en corrected by adjusting the measured hormone concentrations for 
urinary density or urinary creatinine concentration. However, in children, this may lead 
to overcorrection, which has been substantiated for urinary hCG in very dilute samples 
(Alft han, Haglund, Dabek, & Stenman, 1992). Th e correlation between urinary and serum 
levels could not be improved by employing various methods of correction on the U-FSH 
and U-LH levels obtained by IFMA, such as adjusting for urinary density or urinary 
creatinine concentration (I). Interestingly, correction of urinary GH concentrations with 
creatinine did not improve the correlation between urinary and serum GH concentrations, 
either (Main, Philips, Jorgensen, & Skakkebaek, 1991). Until the optimal method for 
correction of urine concentrations has been established, it may be advisable not to perform 
any correction. 
In spite of the strong correlation between the gonadotropin concentrations measured in 
paired urine and serum samples, discrepancies between these occur occasionally (I). High 
urinary but low serum LH values in the morning may be explained by the fact that morning 
urine actually represents the night-time urine collection, in other words, ‘the fi ltered picture 
of the night-time blood circulation’.
4.2 Urinary gonadotropins during pubertal development 
By RIA and (Kulin, 1993) and immunoradiometric methods (Bridges, Matthews, 
Hindmarsh, & Brook, 1994), the age-related changes in urinary gonadotropins have been 
shown to be congruent with those in serum. Th ese fi ndings indicate that determinations of 
U-FSH and U-LH levels by sensitive assays may well be used for evaluation of gonadotropin 
secretion in children. 
Urinary gonadotropin concentrations are generally low (except for the newborn period); 
however, they are almost always detectable throughout prepuberty (Figure 7 and 8). 
During the immediate prepubertal period, U-LH and U-FSH levels were slightly higher 
than those of the respective serum levels. Th e age-dependent changes in U-FSH and U-LH 
concentrations were similar to those reported for serum (Apter et al., 1989; Dunkel et al., 
1990b; Dunkel et al., 1992; Kletter, Padmanabhan, Brown, Reiter, Sizonenko, & Beitins, 
1993a; Bridges, Hindmarsh, Matthews, & Brook, 1994). Because we assayed FMV urine, 
which refl ects the integrated secretion of gonadotropins during night-time, the discrepancy 
between urinary and serum gonadotropin concentrations during the late prepubertal 
period can be attributed to increased pulsatile frequency and amplitude in nocturnal 
gonadotropin secretion (Kletter et al., 1993b), not, of course, to the type of sample.
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Th e U-FSH concentrations were signifi cantly higher in girls than boys aged 2 to 8 years 
(II). By serum assays, the pulsatile secretion of FSH is stronger in girls than boys (Wu et 
al., 1991). Th e biological basis for this diff erence is unknown. During puberty, U-FSH 
concentrations increase approximately 5-fold while those of LH increase 50- to 100-fold 
(III). A similar increase throughout puberty was reported earlier by Kulin and Santner, 
who measured LH by RIA in concentrated extracts of 3 to 24-h urine collections (Kulin & 
Santner, 1977), and more recently by Apter et al., who determined LH and FSH by IFMA in 
serum samples (Apter et al., 1989). 
Fluctuations of serum gonadotropin concentrations in children are problematic in the 
case of single serum determinations (Johanson, 1974). Th is drawback be overcome by 
serial determinations or by a GnRH stimulation test. Th ese require, however, invasive 
sampling and multiple assays. As urine accumulating in the bladder during night refl ects 
the night-time plasma concentrations, the levels of LH and FSH in FMV urine may be 
more informative than random serum samples for detection of early pubertal increases 
in gonadotropin secretion (Bourguignon et al., 1980). On the other hand, gonadotropin 
levels in urine display broader variations than gonadotropin levels in serum, for any given 
age group or pubertal stage (II). Despite this, the age-related changes in U-LH levels are 
clinically meaningful. Th e U-LH concentrations did not overlap at all in the age subgroups 
1-8 and 14-18 years. 
4.3 Urinary gonadotropins for assessing onset of puberty
Th e urinary gonadotropin concentrations measured during sleep and wake periods at 
the onset of puberty presented with a distinct diff erence between these periods, which 
was refl ected even more strongly for LH than FSH levels (Chipman et al., 1981). Serum 
FSH levels remain relatively constant during pubertal development, while the levels of 
testosterone or estradiol levels increase more sharply (Beitins, Padmanabhan, Kasa-
Vubu, Kletter, & Sizonenko, 1990). In agreement with this, we observed that the increase 
in the U-LH/U-FSH ratio was a biochemical marker for the onset of central puberty for 
both boys and girls (III). Th e early morning plasma testosterone concentration among 
boys heralded the onset of puberty (Wu, Brown, Butler, Stirling, & Kelnar, 1993), but a 
corresponding increase in estradiol in girls had never previously been reported to predict 
an approaching onset of puberty. Study III was a large-scale cross-sectional study on the 
FMV U-LH levels and sex steroids in both sexes (III). Since this study was the fi rst to show 
that FMV urine assays reveal the nocturnal increase in LH secretion before clinical signs of 
puberty (III), a longitudinal follow-up of nocturnal urinary gonadotropin concentrations 
(measured from FMV urine samples) combined with pubertal staging is a clinically viable 
method for predicting the onset of female puberty and evaluating the progress of HPG 
activation.  
Th e HPG axis becomes initially activated only during part of the night in relation to the 
onset of deep sleep and occurs a few years before the clinical onset of puberty (Boyar et al., 
1972). Amplifi cation of the pre-existing pulsatile pattern of hypothalamic GnRH secretion 
and an approximately two-fold increase in GnRH pulse frequency initiate the pubertal 
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process, possibly by enhancing sensitivity of the gonadotropic cells. As a result of this, the 
amount of LH produced per burst increases (Wu et al., 1996). Th is short-lived night-time 
activity at the initial phase is not detectable by morning S-LH determinations, but it can be 
identifi ed by determination of LH in FMV urine (II, III). An increase in the amplitude of 
nocturnal LH and FSH secretion bursts is observed for the fi rst time in prepubertal boys 
and girls aged 4–5 years (Mitamura et al., 1999; 2000). Th e amplitude and frequency of 
the gonadotropin secretion peaks increase, and daytime secretion increases as puberty 
advances. In boys, a striking rise in the amplitude of LH secretion bursts is observed in 
serum samples at least 1 year before the clinical signs of puberty are seen (testicular volume 
of at least 3 mL) (Mitamura et al., 1999; 2000; Styne & Grumbach, 2002), whereas the rise 
in FSH levels emerges as a consistently increasing pulse amplitude pattern throughout 
puberty (Spratt & Crowley, 1988; Beitins & Padmanabhan, 1991; Dunkel et al., 1992; Wu et 
al., 1996; Albertsson-Wikland et al., 1997; Styne & Grumbach, 2002).
Th e introduction of ultrasensitive assays made it possible to demonstrate the rapid 
increase in S-LH concentrations during puberty (Stenman et al., 1985; Apter et al., 1989). 
Nonetheless, studies involving a large number of individuals who provided a single daytime 
sample showed that there are changes in mean serum gonadotropin concentrations 
between prepuberty and puberty (Burr et al., 1970; Sizonenko, Burr, Kaplan, & Grumbach, 
1970; August, Grumbach, & Kaplan, 1972; Jenner, Kelch, Kaplan, & Grumbach, 1972; Apter 
et al., 1989). However, single S-LH measurements cannot be relied upon for establishing 
the time when puberty starts. Neely et al. suggested that assessment of the pubertal 
development by random S-LH levels requires very sensitive immunometric assays (Neely, 
Hintz, Wilson, Lee, Gautier, Argente, & Stene, 1995a). Th e short-lived night-time activity 
during the initial phase of activation of the pubertal HPG axis is not detectable by morning 
S-LH determinations, but it can be detected and quantifi ed by LH determinations in FMV 
urine (II, III). We found that there is a strong correlation between S-LH and FMV U-LH 
concentrations measured by the Delfi a assay (I, II). However, 1 to 2 years before the onset 
of puberty, the correlation was weaker, which is apparently due to the night-time increase 
in LH secretion refl ected in FMV urine but not yet in daytime serum samples (III). 
Th e median U-LH concentration increased approximately 75- to 90-fold from the early 
prepubertal to late pubertal age range, while the increase in median U-LH from Tanner 
stage 1 to 5 was 35-fold in boys and 40-fold in girls (II). Th ese results indicate that a 
remarkable increase in U-LH concentrations occurs already in prepubertal boys and girls 
before any clinical signs of puberty. A similar increase in S-LH concentrations occurs later 
in parallel with the development of the clinical signs of puberty. 
Our results also show that the nocturnal increase in LH secretion during late prepuberty, 
or in other words, at the very beginning of puberty were indeed detectable in FMV urinary 
samples up to 4 years before the onset of physical puberty and the increase in S-LH 
concentrations (III). Th ese results conform with those of a previous study, in which a 
gradual prepubertal increase in the nighttime S-LH concentrations of boys correlated with 
an increase in the prepubertal testis volume (Manasco et al., 1995). 
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Th e increase in FMV U-LH preceded the rise in morning S-LH levels and the appearance 
of clinical signs of puberty by 1 to 2 years (III). Th erefore, the early pubertal nighttime 
increase in S-LH levels (Boyar et al., 1972; Boyar et al., 1974; Boyar et al., 1976; Wennink 
et al., 1988; Delemarre-van de Waal, Wennink, & Odink, 1989; Apter et al., 1993) can be 
detected by FMV U-LH determinations and the prepubertal development of pituitary 
gonadotrope function can be assessed already before the clinical onset of puberty. Th is 
fi nding may facilitate early diff erential diagnosis of CDGP from gonadotropin defi ciency. 
Apter et al. also reported a gradual prepubertal enhancement of gonadotropin secretion 
(Apter et al., 1993), which is in agreement with our fi ndings (III). Th e increase in FMV 
U-LH implies that the hypothalamic GnRH pulse generator which initiates biochemical 
puberty is activated at about the same time for boys and girls (III), although the fi rst 
physical signs of puberty are usually detectable earlier in girls than in boys.
A considerable part (about 15-fold) of the overall increase in U-LH concentrations during 
biochemical puberty in boys occurs before clinical signs of puberty between ages 7 and 12 
years. Th e use of a testicular volume above 3 mL as a defi nite clinical sign of puberty may 
cause a misclassifi cation of some boys as prepubertal, although they in fact have ‘subclinical 
puberty’. 
In girls, the rise in FMV U-LH concentrations (between 7-8 and 9-10 years) was not 
refl ected in clinical signs of puberty, as all girls in this age range in our third study were 
classifi ed as prepubertal (III). Clinical puberty was observed only aft er a 10-fold increase in 
FMV U-LH and this took place aft er age 11 years (III).
Th e fact that variations in bone age have not been taken into account in assessing the course 
of urinary gonadotropins related to chronological age or pubertal stage can be regarded as a 
limitation of our study design. However, no subject with any disorder of growth or puberty 
was admitted into studies II and III, where the main focus was on the course of urinary 
gonadotropins by chronological age or pubertal stage. Besides, studying the nature of sleep 
while investigating the course of urinary gonadotropins along with pubertal development 
can be an additional improvement over the study design presented here; and again, it is 
quite uncommon that children would have sleeping disorders that would hinder the 
occurrence of deep sleep.
4.4 Clinical use of urinary gonadotropin measurements
FMV U-LH concentrations in the serum or urine of subjects being studied for growth 
or pubertal disorders (mainly short or tall stature and suspected precocious or delayed 
puberty) (IV) also correlated strongly with the basal S-LH levels. Th is fi nding agrees with 
our studies on children and adolescents with no growth or pubertal disorders (I-III).
Th e correlations between FMV U-LH and S-LHmax as well as between the FMV U-LH/U-
FSH ratio and the S-LHmax/S-FSHmax ratio were both very strong (IV). Th ese fi ndings 
are in conformity with those reported by Witchel et al., who reported a strong correlation 
between 24-h U-LH and S-LHmax in 18 girls on GnRH analog treatment for precocious 
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puberty (Witchel, Baens-Bailon, & Lee, 1996) and by Zung et al. who reported a strong 
correlation between FMV U-LH and S-LHmax and the S-LHmax/S-FSHmax ratio in 47 
girls being studied for precocious puberty (Zung, Burundukov, Ulman, Glaser, Rosenberg, 
Chen, & Zadik, 2014). 
U-LH concentrations and the U-LH/U-FSH ratio correlated at least equally well as 
S-LHmax and the S-LHmax/S-FSHmax ratio with the pubertal developmental stage. Th e 
FMV U-LH and S-LHmax levels as well as the U-LH/U-FSH and S-LHmax/S-LHmax 
ratios increased signifi cantly between the prepubertal and early pubertal stage in both 
sexes (G1 vs. G2 and B1 vs. B2), but there was still signifi cant overlapping between the 
pubertal stages. Th us, separation between the prepubertal and early pubertal stages was 
not complete. Th e results of study III were subsequently confi rmed by Maqsood et al. 
(Maqsood, Trueman, Whatmore, Westwood, Price, Hall, & Clayton, 2007) and McNeilly et 
al. (McNeilly et al., 2012).
ROC curve analyses showed that the AUC values for FMV U-LH and U-LH/U-FSH 
predicted clinical puberty (Tanner B/G stage 2) slightly better than the GnRH stimulation 
test, particularly for girls. Th e sensitivity of the GnRH stimulation test to identify clinical 
puberty was rather low (59%) but at the same sensitivity level, U-LH and the U-LH/U-FSH 
ratio were more specifi c (96% and 79%, respectively) than the GnRH test (66%).
Of the boys 38% and of the girls 8% classifi ed as prepubertal by Tanner staging had evidence 
of early puberty on the basis of the FMV U-LH concentration; the corresponding fi gures 
for the GnRH-test were 23% for the boys and 13% for girls (IV). Th is is in accordance 
with previous studies reporting activation of the HPG axis before clinical manifestations 
of puberty (Apter et al., 1993; II; III). However, the fairly high rate of apparently “false 
negative” U-LH and GnRH test results especially among the girls could also be caused 
by erroneous Tanner staging due to breast development initiated by other endocrine 
factors than gonadotropins and ovarian estrogens. Tanner staging is more subjective for 
girls than boys. A too high Tanner breast stage in girls may occasionally be due to a false 
interpretation of benign premature thelarche as a sign of puberty: there may be excessive 
palpable adipose tissue or precocious pseudopuberty. Precocious pseudopuberty may be 
due to congenital adrenal hyperplasia, tumors that secrete hCG, tumors of the adrenal gland 
or ovary, exposure to exogenous sex steroid hormones from oral contraceptives or cosmetic 
products, vitamins, or dietary supplements that may contain estrogenic substances, e.g., 
placental extracts, or to excess consumption of soy or similar plant-derived xenoestrogens 
(phytoestrogens). In general, U-LH measurements worked well for evaluation of pubertal 
development in both sexes. On the other hand, with the current cut-off  values, the GnRH 
test does not seem to be as reliable in girls as in boys as a method to identify clinical puberty.
When determined by suffi  ciently sensitive methods, a random S-LH measurement is useful 
for separating pubertal stages more clearly and S-LH be suggested as a useful screening 
method for evaluating children with CPP and DP (Garibaldi, Picco, Magier, Chevli, & 
Aceto, 1991). Th e basal concentrations of serum LH diagnoses CPP in more than 90% of 
the girls (Houk, Kunselman, & Lee, 2009). Th e diagnostic accuracy of serum gonadotropin 
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measurements can be improved by using the GnRH stimulation test, the gold standard for 
determining HPG activity. 
Setting cut-off  values for a pubertal response for the GnRH test results has been quite 
demanding in girls, as reviewed recently by Zung et al. (Zung et al., 2014). Based on the 95th 
percentile of the S-LH levels of healthy prepubertal girls undergoing the GnRH test, Brito et 
al. (Brito, Batista, Borges, Latronico, Kohek, Th irone, Jorge, Arnhold, & Mendonca, 1999) 
suggested a S-LHmax cut-off  level of 6.9 IU/L. Resende et al. (Resende, Lara, Reis, Ferreira, 
Pereira, & Borges, 2007) suggested a cut-off  level of 3.3 IU/L (ICMA) or 4.2 IU/L (IFMA) 
for S-LHmax, and Neely et al. (Neely et al., 1995a) suggested 5 IU/L as the S-LHmax cutoff  
value (which is 2 SD above the mean in prepubertal girls) or alternatively 8 IU/L (4 SD 
above the mean). Th e 5 IU/L threshold has been adopted by many researchers (Oerter, 
Uriarte, Rose, Barnes, & Cutler, 1990; Neely et al., 1995a; Neely, Wilson, Lee, Stene, & 
Hintz, 1995b; de Vries, Horev, Schwartz, & Phillip, 2006; Mogensen, Aksglaede, Mouritsen, 
Sorensen, Main, Gideon, & Juul, 2011). A single S-LH concentration of >4 IU/L 30–60 min 
aft er injection of GnRH has been proposed to indicate the onset of puberty (Cavallo & 
Zhou, 1994). Likewise, a single S-LH concentration of ≥15 IU/L at 30 min aft er injection of 
GnRH may be as useful as the peak LH in the GnRH test for diagnosing CPP (Cavallo et 
al., 1995). 
Th e results from our latest study (IV) suggest that the S-LHmax cut-off  value for girls may 
be slightly lower than for boys in the GnRH test. Th is view is indirectly supported by the 
slightly lower cut-off  values for U-LH in girls than boys based on ROC curve analyses (IV). 
Determination of basal S-LH concentrations is also suitable for evaluation of the pubertal 
stage if blood is to be drawn for other reasons. However, our results show that neither 
boys nor girls require measurement of S-LH nor a GnRH test for the initial evaluation of 
pubertal stage. Determination of S-LH in children is reliable only if the assay is sensitive 
enough to measure concentrations in the range 0.02-0.04 IU/L, which correspond to the 
cut-off  values (IV). Because of the somewhat higher U-LH than S-LH concentrations, a 
single measurement of LH in FMV urine provides information about pubertal stage that is 
at least as reliable as measurement of S-LH or the GnRH stimulation test. 
A possible limitation of the FMV U-LH assays is related to the fact that a large part of the 
LH immunoreactivity in urine is caused by the LH core fragment (LHβcf), a fragment of 
the β-subunit of LH (Birken, McChesney, Yershova, Gaughan, Pettersson, Rechenberg, Wu, 
& Taliadouros, 2007). Diff erent assays recognize this fragment to variable extent, and the 
LH concentrations are therefore highly dependent on the assay (Singh et al., 2013). Poor 
stability of LH in urine is another problem if urine is stored frozen before assay, since much 
of LH may be degraded during storage at -20 °C (I; (Singh et al., 2013). 
When interpreting the results of study IV, it should be noted that the fi ndings are based on 
patients referred for investigation of various growth and pubertal disorders. Th is means 
that the concentrations of FMV U-LH and U-FSH in that study may not be appropriate 
reference values for healthy children. We have previously prepared reference values for 
healthy children for FMV U-LH and U-FSH (II) and U-LH with the LHspec assay using 
IFMA methodology (III). However, there are some upfront shortcomings of the above-
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mentioned sets of ‘normative’ data: 1) the results are based on cross-sectional data, 2) 
considering diff erent sex, age and pubertal stage groups, the number of subjects per any 
given age/pubertal stage group of either sex is rather limited and conclusions must be 
drawn cautiously, 3) the subjects were referred to an outpatient clinic because of some 
clinical matter; therefore there may be a slight disadvantage over a clinical study design 
with exclusively fully healthy subjects. Also, any other LH or FSH assay should be validated 
for use on urine samples and method-specifi c reference values have to be established.
In conclusion, we have shown that measurement of FMV U-LH and the U-LH/U-FSH 
ratio can be used as a non-invasive method for assessment of pubertal maturation and its 
disorders. Th is reduces the need for invasive GnRH stimulation tests and for drawing blood 
for serum assays. Determination of FMV U-LH should also be useful for monitoring the 
progression and treatment of precocious puberty (Zung et al., 2014).
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FUTURE PERSPECTIVES
Clinical use of urinary gonadotropin measurements has not been studied in depth since 
our fi rst study (I). Th is is probably due to the fact that collecting an additional urine sample 
has not been a favored method of choice in the clinical evaluation of pubertal development, 
since the prospects of obtaining additional information through urinary gonadotropin 
measurements have not been established. Th ere are no solid reference values for urinary 
gonadotropins for subgroups of sex, age and pubertal stage, in particular in relation to 
various pathological states. Also, very few LH assays, apart from IFMA, with suffi  cient 
sensitivity have been available and the AutoDelfi a analyzer for mass IFMA applications has 
not been widely used. Besides, the sensitivity of S-LH, S-FSH, S-testosterone and S-estrogen 
assays suitable for common autoanalyzers has improved substantially over the last two 
decades. Study IV showed that AUC values for S-LH and FMV U-LH present quite similar 
levels. Th ere is, nevertheless, still room for using urinary gonadotropin measurements, 
but reference ranges for suffi  ciently large, healthy groups by sex, age and pubertal stage 
are needed, and the same goes for patients with a confi rmed diagnosis of some pubertal 
disorders.
Diff erent diagnostic subgroups should be studied with regard to HPG axis function 
in terms of (urinary) gonadotropins and sex steroids. A suffi  cient number of subjects is 
needed per disorder, sex, age and pubertal stage because observations may diff er between 
children suspected for disorders of pubertal development and those suspected for only a 
somatic growth disorder. 
Further studies should be designed to investigate the usefulness of repeated FMV 
gonadotropin determinations within a short time frame and over a long period of time. 
Determination of FMV U-LH may be valuable for the diff erential diagnosis of pubertal 
disorders, which might reduce the need to initiate treatment in adolescents with CDGP 
having already clearly increasing U-LH concentrations.
FMV U-LH may also be valuable for following up the treatment outcome of patients with 
pubertal disorders, e.g., during follow-up of GnRH analogue treatment in patients with 
CPP.
Since urinary gonadotropin measurements are practical and easily repeated at regular 
intervals, it would be useful to examine the added value of repeated analyses of U-LH, 
U-FSH or the U-LH/U-FSH ratio for evaluating pubertal development and pubertal 
disorders. In addition to the studies in this book, we have collected clinical and laboratory 
data of 30 subjects for a period of over 10 years, the analyses of which should provide 
valuable data for our understanding of the true relationship between chemical and clinical 
onset of puberty in individual cases. Th is study should provide valuable information on the 
expected time to the onset of puberty is, i.e, on how to predict puberty, not merely identify 
it. It should also help clinicians re-evaluate the currently established criteria for confi rming 
true puberty.
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We have further cross-sectional data based on 3 repeated FMV urine samples from over 
500 subjects. I hope that designing this study will also further benefi t our understanding of 
the clinical utility of urinary gonadotropin measurements. 
We have gathered yet another unpublished set of longitudinal data, which comes from 40 
newborns or infants younger than 6 months. Th e analysis of that data will provide further 
valuable information on this topic.
Future Perspec? ves
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CONCLUSIONS
Gonadotropin concentrations in FMV urine reveal activation of the HPG axis earlier than 
the fi rst clinical manifestations of puberty or the concentrations of gonadotropins in day-
time serum samples. Th is is due to the fact that gonadotropins measured in samples of 
urine accumulated in the bladder overnight express the integrated night-time secretion 
of gonadotropins, and thus the average night-time gonadotropin concentrations in the 
plasma. 
Th e clinical use of urinary gonadotropin measurements should be facilitated, since the 
method provides a non-invasive estimate of gonadotropin secretion in healthy children 
and adolescents, and in subjects with pubertal development disorders. Th e appropriate use 
of urinary gonadotropin measurements should ultimately reduce the need for the GnRH 
stimulation test and for blood sampling for serum gonadotropin assessments. 
Conclusions
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